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                                        1.INTRODUCTION 
  A drug is, in the broadest of terms a chemical substance that has known 
biological effect on humans  or other animals. In pharmacology, a drug  is a 
chemical substance used in the treatment, cure, prevention, or diagnosis of disease 
or used to otherwise enhance physical or mental well being . Pharmaceutical drugs 
may be used for a limited duration, or on a regular basis for chronic disorders.  
               Pharmaceutical industry, the discovery, development and manufacture of 
drugs and medications by public and  private organizations. The  modernera of the 
pharmaceutical industry of isolation and purification of compounds, chemical 
synthesis and computer- aided drug design is considered to have begun in the 19th 
century thousands of years after intuition and trial and error led humans to believe 
that plants, animals, and minerals contained medicinal properties. The unification 
of research in the 20th century in fields such as chemistry and physiology increased 
the understanding of basic drug discovery processes. Identifying new drug targets, 
attaining regulatory approval from governments agencies and refining techniques 
in drug discovery and development are among the challenges that face the 
pharmaceutical evoluation and advancement of the control and elimination of 
disease around the world. 
 In the preparation of dosages, many pharmaceuticals are ground to varying 
degrees of fineness. Many medicinal substances are added to water , alcohol, or 
another solvent so that they can be used in solution form. These may  include 
spirits, elixers and tinctures. Ointments are one of many semisolid preparations, 
which also include creams, pastes and jellies. Solid pharmaceuticals include pills, 
tablets, lozenges and suppositories. In this form the compounds are more stables, 
with less risk of chemical reaction, and the dosage is easier to determine. Storage 
and packaging  also is made simpler, and solid forms are more efficient produce.    
ADMINISTERING DRUGS:   
                Drugs, both medicinal and recreational can be administered in a number 
of ways or routes. Many drugs can be administered via more than one route.  
Bolus is the administration of a medication, drug or other compound that is given 
to raise its concentration in blood to an effective level. The administration can be 
given intravenously, by intramuscular, intrathecal or subcutaneous injection. 
   *Inhaled,( breathed into the lungs) as an aerosol or dry powder. 
  *Injected as a solution, suspension or emulsion either : Intramuscular, 
intravenous, intraperitoneal, intraosseous.   
   *Insufflation or snorted into the nose.   
   *Orally as a liquid or solid, that is absorbed through the intestines.   
   *Rectally as a suppository, that is absorbed to the rectum or colon.    
   *Sublingually, diffusing into the blood through tissues under the tongue.   
   *Topically, usually as a cream or ointment. A drug administered in this manner 
may be given to act locally or systematically.  
    *Vaginally as a suppository, primarily to treat vaginal infections.  
Any drug delivery system is based on the nature of disease  and its causing agent 
as well as the anatomy andphysiology of affected organ. 
RESPIRATORY PROBLEMS:    
                              In humans the anatomical features of the respiratory system 
include airways, lungs and the respiratory muscles. Molecules of oxygen and 
carbon-di-oxide are passively exchanged, by diffusion, between the gaseous 
external environment and the blood. This exchange process occur in the alveolar 
region of the lungs. The respiratory system can be subdivided into an upper 
respiratory tract and a lower respiratory tract based on the anatomical features. 
The upper respiratory tract includes the nasal passages, pharynx and larynx, while 
the lower respiratory tract is comprised of the trachea, the primary bronchi and 
lungs.    
DISORDER OF THE RESPIRATORY SYSTEM CAN BE CLASSIFIED INTO 
FOUR GENERAL AREAS:   
1) OBSTRUCTIVE CONDITIONS:  Emphysema, bronchitis, asthma 
attacks.   
2) RESTRICTIVE CONDITIONS : Fibrosis, sarcoidosis, alveolar 
damage, pleural effusion.   
 3) VASCULAR DISEASE:  Pulmonary edema, pulmonary embolism, 
pulmonary hypertension.   
 
 
4) INFECTIOUS, ENVIRONMENTAL AND OTHER DISEASES: 
Pneumonia, tuberculosis, asbestosis, particulate pollutants.   
 
COMMON RESPIRATORY DISORDERS INCLUDE:    
            *CHRONIC OBSTRUCTIVE PULMONARY DISEASE(COPD): 
Irritation of the lungs can lead to asthma, emphysema and chronic bronchitis and 
people can develop two or three of these together.   
                   1) CHRONIC BRONCHITIS; Any irritant reaching the bronchi and 
bronchioles will stimulate an increased secreation of mucus. In chronic bronchitis 
the air passages become clogged with mucus and this leads to a peristant cough.   
                    2) ACUTE BRONCHITIS:  It is a shorter illness that commonly 
follows a cold  or irral infection such as the flu. It I consists of a cough with 
mucus, chest dis comfort or soreness, fever and sometimes shortness of breath. 
Acute bronchitis usually lasts a few days on weeks.  
SYMPTOMS FOR BOTH ACUTE AND CHRONIC BRONCHITIS:   
i)Peristant cough may produce mucus.     ii)Wheezing      iii)Low fever and chills   
iv)Chest tightening      v)Sore throat        vi)Body ache     vii) Breathlessness    
viii)Headache       ix)Blocked nose and sinuses.    
EMPHYSEMA: The delicate walls of the alveoli break down, reducing the gas 
exchange area of the lungs. The condition develops slowly and is seldom a direct 
cause of death.   
ASTHMA: Periodic constriction of the bronchi and bronchioles makes it more 
difficult to breathe.   
PNEUMONIA: Any infection of the alveoli. It can be caused by many kinds of 
both bacteria viruses. Tissue fluids accumulate in the alveoli reducing the surface 
 area exposed to air. If enough alveoli are affected, the patient may need 
supplemental oxygen. 
ROLE OF CLARITHROMYCIN:    
           Immediate release drug delivery system are based on single or multiple unit 
reservoir or matrix system, which are designed to provide of time. Immediate 
release drug delivery is desirable for drugs having long biological half life, high 
bioavailability. Oral drug delivery is the most desirable and preferred method 
administering therapeutics agent for their systematic effect. In addition, the oral 
medication is generally considered as the first avenue investigated in the discovery 
and development of new entities and pharmaceutical formulation, mainly because 
of patient acceptance, convenience in administration and cost effective 
manufacturing process.  
                      Clarithromycin is a macrolide antibiotic with broad spectrum of 
activity. It is given the treatment of respiratory tract infection in the skin and soft 
tissue infection. Clarithromycin may be given to eradicate H.pylori in treatment 
regimen’s for peptic ulcer diseases. Clarithromycin has invitro antibacterial 
activity against typical ( streptococcus, pneumonia, haemophilus, influenza, 
Moraxella catarhalis) atypical ( mycoplasma pneumonia, chlamydia pneumonia, 
legionella pneumophilla ) pathogens commonly associated acquired lower 
respiratory tract infections. 
                          Clarithromycin is rapidly absorbed from the GIT and undergoes 
first pass metabolism. The bioavailability of the drug is about 55% . The terminal 
half life of clarithromycin is reportedly  about 3-4 hrs. Compared with 
erythromycin, clarithromycin possesses greater acid stability, improved 
pharmacokinetic properties and fewer GIT, rapid gastrointestinal absorption, 
highly soluble at acidic pH absorption of clarithromycin is unaffected by food. 
More than half of an oral dose is systematically available as the parent drug and 
the active 14- hydroxyl metabolite, pharmacokinetics are non linear, with plasma 
concentration increasing in more than proportion to the dosage. First pass 
metabolism results in the rapid appearance of the active metabolite. 14-Hydroxy 
clarithromycin and its active metabolite are found in greater concentrations in the 
tissue and fluids of the respirator, it has higher eradication rate invivo to H.pylori. 
The recommended dosage regimen for these types of infection in adult patients is 
 250mg to 500mg twice daily for 7-14 days of the immediate- release oral 
formulation of clarithromycin.  
MEDICATIONS 6 
         Therapy addressing specific symptoms is the mainstay for most URIs. Most 
URIs are self-limited viral infections, which can be resolved without prescription 
of drugs. Recognizing viral and bacterial diseases for which specific therapy is 
available is important. Antibacterial therapy is useful for patients with group A 
streptococcal pharyngitis, bacterial sinusitis, epiglottis’s, pertussis, or diphtheria. 
Patients with HSVinfection or gonococcal upper airway disease also benefit from 
specific treatment. In immune compromised patients, infections may be 
appropriate, especially if lower airway disease is suspected. In general, antiviral do 
not provide clinical benefits in persons with viral pharyngitis. However, in patients 
who are immune compromised, antiviral have a role in treating illness that might 
progress. Acyclovir, famciclovir, and valacyclovir are recommended for patients 
with severe HSV pharyngitis and for immune compromised patients. Ganciclovir 
or foscarnet are recommended for the treatment of cytomegalovirus infections in 
immune compromised patients.   
1.2. CHEMOTHERAPY7,8,9,10 
Chemotherapy can be defined as the use of chemical in infectious  diseases  to  
destroy the microorganisms without damaging the host tissues. 
1.2.1. ANTIBIOTICS: 
Antibiotics are substances produced by a microorganism that suppresses the 
growth of or destroy  other microorganisms. 
1.2.2. CLASSIFICATION: 
Antibiotics are classified in many ways based on chemical structure, its spectrum 
of activity, pharmacological activity. 
1.Basedonchemicalstructure7     
ANTIBIOTICS  
1.SULPHONAMIDES : Sulphamethaoxazole, Sulphadiazine,   
 Sulphamethaoxazole+Trimethaprim. 
2.QUINOLONES          : Nalidixic acid, Ciproflaxacin, oflaxacin,  Levoflaxacin  
3.B-LACTUM               : Penicillin, ampicillin, amoxicillin, cephalosporins   
4.TETRACYCLINES    : Doxycyclines   
5.MACROLIDES          : Erythromycin, Azithromycin, Clarithromycin, 
Telithromycin  
6.AMINOGLYCOCIDES :  Streptomycin, Neomycin, Gentamycin, kanamycin.s 
2. Based on mechanism of action 
1. Inhibit cell wall synthesis 
• Penicillins, cephalosporins, carbapenems, monobactam, vancomycin,  
bacitracin,   cycloserine. 
2. Damage cell membranes(cause leakage of cell membranes) 
• Polymyxins, amphotericin B, nystatin. 
3. Bind to ribosomes and inhibit protein synthesis: 
• Chloramphenicol, tetracyclines, erythromycin, amino glycosides, 
clindamycin. 
4. Inhibit DNA gyrase 
• Flouroquinolones 
5. Inhibit DNA function 
• Rifampicin 
6. Interfere with metabolic steps 
• Sulphonamides, sulphones, trimethoprim, pyrimethamine. 
Antimicrobials may also be classified as extent of action: 
1. Bacteriostatic: 
  These are the agents that suppress the growth of bacteria. 
Eg: Sulphonamides, Tetracyclines, Linezolid, Chloramphenicol, Clindamycin. 
2. Bactericidal: 
  These are the agents that kill the bacteria. 
E.g: Penicillins, Cephalosporins, Amino glycosides, Flouroquinolones, 
Rifampicin, Metronidazole.              
 However, some drugs may be bacteriostatic at low doses and bactericidal 
at higher doses. E.g: Erythromycin may be bacteriostatic to some microorganisms 
and bactericidal to others. Eg: Chloramphenicol is bactericidal to H.influenzae, 
S.pneumoniae and N.menigitidis, while it is bacteriostatic to other 
microorganisms. 
 
1.2.3. ANTIBACTERIAL SPECTRUM: 
 An antimicrobial may have a narrow or broad spectrum of activity. 
 Narrow spectrum antibiotics: 
           E.g: penicillin G – gram positive organisms   
Amino glycosides –gram negative organisms. 
 Broad spectrum antibiotics: 
     E.g:   Tetracyclines  and Chloramphenicol: gram positive  and gram negative 
organisms, ricketssiae, chlamydiae, mycoplasma. 
  Broad spectrum antibiotics are so called because in addition to suppression 
of gram positive and gram negative bacteria, they also inhibit the growth of other 
microorganisms like ricketssiae, chlamydiae, mycoplasma and some protozoa. But 
in practice the term ‘broad spectrum’ is often used to include all antimicrobials 
with a wide spectrum of activity i.e., those effective against both gram positive 
and gram negative organisms.  
E.g: Ampicilin. 
 1.2.4. MACROLIDES7,8 ,9,10,11 
Macrolide are group of antibiotics produced by various strains of 
streptomyces. They have three common chemical characteristics like a large non-
planar strain less ring, a keto group, a glycosidically linked amino sugar.Usually 
the lactone ring has 12, 14 or 16 atoms in it, unsaturated with an olefinic group 
conjugated with the ketone function. They may have a neutral sugar also, in 
addition to the amino sugar, which is linked glycosidically to the lactone ring. 
The macrolides are a group of antibiotics with a structure to which one or 
more deoxy sugars are attached. Erythromycin was the first of these drugs to find 
clinical application, both as a drug of first choice and as an alternative to penicillin 
in individuals who are allergic to lactam antibiotics. The newer members of this 
family, clarithromycin (a methylated form of erythromycin) and azithromycin 
(having a larger lactone ring), have some features in common with, and others that 
improve on, erythromycin. Telithromycin, a semi synthetic derivative of 
erythromycin, is the first ketolide• antimicrobial agent that has been approved and 
is now in clinical use. 
  Ketolides and macrolides have very similar antimicrobial coverage. 
However, the ketolides are active against many macrolide-resistant gram-positive 
strains. 
MECHANISM OF ACTION: 
Macrolides are protein synthesis inhibitors. The mechanism of action of 
macrolides is inhibition of bacterial protein biosynthesis, The drugs act by binding 
to cell membranes and causing changes in protein function and they are thought to 
do this by preventing peptidyltransferase from adding the peptidyl attached to t-
RNA to the next amino acid as well as inhibiting ribosomal translocation. Another 
potential mechanism is premature dissociation of the peptidyl-tRNA from the 
ribosome. 
Macrolide antibiotics do so by binding reversibly to the P site on the 
subunit 50S of the bacterial ribosome. Macrolides inhibit the translocation of the 
growing peptide chain from A site to P site. Hence A site is not available for 
binding of next aminoacid (brought by t-RNA). This action is mainly 
bacteriostatic, but can also be bactericidal in high concentrations. Macrolides tend 
 to accumulate within leukocytes, and are, therefore, transported into the site of 
infection. 
ERYTHROMYCIN: 
           It is a fermentation product of the fungus streptomyces erythreus. Its 
antibacterial spectrum resembles that penicillin. It is mainly effective against gram 
positive cocci including the streptococci, staphylococci and pneumococci, 
Neisseria, some strains of H. influenza, C.diphtheriae, Mycoplasma pneumonia, 
Rickettsiae and Treponemas are also inhibited by low concentration. The drug is 
effective against penicillin resistant staphylococci can develop resistance to 
erythromycin. Its activity increases with an increase of pH upto 8.  
ROXITHROMYCIN: 
It is a newer macrolide (azalides) have a similar spectrum of activity as 
erythromycin. They are acid stable, longer acting, more potent, better absorbed 
and has a better tissue penetrability compared to erythromycin. It is rapidly 
absorbed from the gut with a bioavailability of 50%, food interferes with its 
absorption.  Most of the drug is excreted either through feces, unchanged or as 
metabolites. The adverse effects are similar to that of erythromycin. It should be 
taken before 30 min of food. It is used in ear, throat, respiratory tract and non-
gonococcal genitourinary infections. It is more expensive. 
AZITHROMYCIN: 
This azilide antibiotic differs chemically from the macrolide group in that 
the lactone ring contains a nitrogen atom. It has similar activity as erythromycin 
but in addition, it act against gram-positive bacilli including H.influenzae. It also 
act against Mycobacterium avium complex (MAC). It is most active at pH 7.4 and 
above. It has better tissue penetrability, longer half-life than erythromycin. It can 
be used in respiratory tract infections, cervicitis and urethritis. 
KETOLIDES 
Ketolides are modified macrolides that are similar to newer macrolides  and 
also  related to erythromycin with similar antibacterial spectrum. The main 
example of this category is Telithromycin. It is resistant to pneumococci.  The 
drug is potent inhibitor of CYP3A4. 
 1.4. INTRODUCTION FOR TABLETS: 
The oral route of drug administration is the most important method of 
administrating drugs for systemic effects. Oral drug delivery has been known for 
decades as the most widely utilized route of administered among all the routes that 
have been employed for the systemic delivery of drug via various pharmaceutical 
products of different dosage forms. The reasons that the oral route achieved such 
popularity may be in part attributed to its ease of administration belief that by oral 
administration of the drug is well absorbed. 
    All the pharmaceutical products formulated for systemic delivery via the 
oral route of administration irrespective of the mode of delivery (immediate, 
sustained or controlled release) and the design of dosage forms (either solid 
dispersion or liquid), must be developed within the intrinsic characteristics of GI 
physiology, pharmacokinetics, pharmacodynamics and formulation design is 
essential to achieve a systemic approach to the successful development of an oral 
pharmaceutical dosage form.   
1.4.1. TABLETS13,15,16,17,18,19.20,21,22.23.24.25.26 
 Tablets are solid dosage forms containing medicinal substances with or 
without suitable diluents. They are the most widely preferred form of medication 
both by pharmaceutical manufacturer as well as physicians and patients. They 
offer safe and convenient ways of active pharmaceutical ingredients (API) 
administration with excellent physiochemical stability in comparison to some 
other dosage forms, and provide accurate dosing. 
They can be mass-produced with robust quality controls and other different 
branding possibilities by means of colored film coating different sizes and shapes. 
Tablets are usually solid, right circular cylinders, the end surfaces of which are flat 
or convex and the edges of which may be bevelled. 
1.4.2. PROPERTIES OF TABLETS  
The attributes of an acceptable tablet are as follows: 
• The tablet must be sufficiently strong and resistance to shock and abrasion 
and to withstand handling during manufacturing, packaging, shipping and use. 
Hardness and friability tests measure this property.       
 • Tablet must be uniform in weight and in drug content of the individual 
tablet. 
• This is measured by the weight variation and content uniformity tests. 
• The drug content of the tablet must be bioavailable. This property is 
measured by the dissolution test. Accurate bioavailability can be obtained from the 
drug levels of the drug after its administration 
• Tablets must be elegant in appearance and must have characteristic shape, 
color and other markings necessary to identify the product. 
• Tablets must retain all these functional attributes, which include drug 
stability and efficacy.  
ADVANTAGES OF TABLETS 15   
• They are easy to administer. 
• They are a unit dosage form, and they offer the greater capabilities of all 
oral dosage forms for the greatest dose precision and the least content variability. 
• Their cost is lowest of all oral dosage forms. 
• They are the lightest and most compact of all oral dosage forms. 
• Product identification is potentially the simplest and cheapest, requiring no 
additional processing steps when employing an embossed or monogrammed punch 
face. 
• They are in general the easiest and cheapest to package and ship of all oral 
dosage forms. 
• They may provide the greatest ease of swallowing with least tendency for 
“hang-up” above the stomach. Especially when coated, provided that tablet 
disintegration is not excessively rapid. 
• They tend themselves to certain special release profile products, such as 
enteric or delayed release products. 
• They are better suited to large-scale production than other unit oral forms. 
 They have the best-combined properties of chemical, mechanical and 
microbiological stability of all the oral forms. 
• One of the major advantages of tablet over capsules is that the tablet is 
essentially “tamperproof dosage form.” 
2.   DISADVANTAGE OF TABLETS 15 
• Some drugs resist compression into dense compacts, owing to their 
amorphous nature or flocculent, low-density character. 
• Drugs with poor wetting, slow dissolution properties, intermediate to large 
dosages, optimum absorption high in the gastrointestinal tract, or any combination 
of these features may be difficult or impossible to formulate and manufacture as a 
tablet that will still provide adequate or full drug bioavailability. 
• Bitter tasting drugs, drugs with objectionable odor or drugs that are 
sensitive to oxygen or atmospheric moisture may require encapsulation or a 
special type of coating which may increase the weight of the finished products. 
• A major disadvantage of capsules over tablets is their higher cost. 
TYPES OF TABLET 16,17 
 The main reasons behind formulation of different types of tablets are to 
create a delivery system that is relatively simple, inexpensive to manufacturer, 
dosage form that is convenient from patient’s perspective and utilize an approach 
that is un-likely to add complexity during regulatory approval process. To 
understand each dosage form, tablets here are classified by their route of 
administration, by the type of drug delivery system and by the formulation 
characterized. 
ORAL TABLETS FOR INGESTION 
These tablets are meant to be swallowed intact along with a sufficient 
quantity of water. Exception is chewable tablet. Over 90% of the tablets 
manufactured today are ingested orally. This shows that this class of formulation 
is the most popular worldwide and the major attention of the researcher is towards 
this direction. 
These include: 
 1. Standard compressed tablets 
2. Multiple compressed tablets 
• Compression coated tablet 
• Layered tablet 
• Inlay tablet 
3. Modified Release tablet 
4. Delayed action tablet 
5. Targeted tablet 
• Floating tablet 
• Colon targeting tablet 
6. Chewable tablet 
7. Dispersible tablet 
Tablets used in the oral cavity 
The tablets under this group release API in oral cavity or to provide local 
action in this region. The tablets under this category avoids first-pass metabolism, 
decomposition in gastric environment, nauseatic sensations and gives rapid onset 
of action. The tablets formulated for this region are designed to fit in proper region 
of oral cavity. These include: 
 Lozenges and troches 
 Sublingual tablet 
 Buccal tablet 
 Dental cones 
 Mouth dissolved tablet 
Tablets administered by other routes 
 The tablets administered by other route, which avoid from passing through 
gastro intestinal tract. These tablets may be inserted into other body cavities or 
directly placed below the skin to be absorbed into systemic circulation from the 
site of application. These include: 
 
 Vaginal tablet 
 Implants  
Formulation characteristics 
Tablets are also classified according to their formulation characteristics such as 
 Immediate release tablets 
 Effervescent tablets 
 Melt in mouth or fast dissolving tablets 
 Delayed release or extended release tablets            
1.4.9.MANUFACTURING DEFECTS IN TABLETS18  
 Processing problems are categorized into following are:           
1. Defects during tablet processing : 
• Capping 
• Lamination 
• Cracking 
• Picking 
• Sticking/filming 
• Binding 
• Chipping 
 
 2. Defects due to other factors : 
• Mottling 
3. Defects due to machine : 
• Poor flow pattern 
• Double impression 
 
 
1.4.10.   TABLET  COATING15,19,20 
 Coated tablets are defined as “tablets covered with one or more layers of 
mixture of various substances such as natural or synthetic resins, gums, inactive 
and insoluble filler, sugar, plasticizer, polyhydric alcohol, waxes, authorized 
coloring material and sometimes flavoring material . 
Coating may also contain active ingredient. Substances used for coating are 
usually applied as solution or suspension under conditions where vehicle 
evaporates. 
A) ASPECTS OF TABLET COATING 
I. THERAPY 
i) Avoid irritation of oesophagus and stomach 
ii) Masks bitterness 
iii) Avoid inactivation of drug in the stomach 
iv) Improve drug effectiveness 
v) Prolong dosing interval 
vii) Improve patient compliance 
II. TECHNOLOGY 
 i) Reduce influence of moisture 
 ii) Avoid dust formation 
iii) Reduce influence of atmosphere 
iv) Improve drug stability 
v) Prolong shelf life 
III. FORMULATION 
i) Withstand mechanical process 
ii) Maximum adhesion of the coating to the tablet surface, especially when a 
logo is present 
iii) A smooth film coat with uniform thickness 
IV. MARKETING 
i) Improve product identity 
ii)Improve appearance and acceptability 
B) BASIC PRINCIPLE OF TABLET COATING 19,20 
The principle of tablet coating is relatively simple. Tablet coating is the 
application of coating composition to moving bed of tablets with concurrent use of 
heated air to facilitate evaporation of solvent. 
C) TYPES OF TABLET COATING PROCESS 
1.SUGAR COATING 
Compressed tablets may be coated with colored or uncolored sugar layer. 
The coating is water soluble and quickly dissolves after swallowing. Sugarcoat 
protects the enclosed drug from the environment and provides a barrier to 
objectionable taste or order. The sugar coat also enhances the appearance of the 
compressed tablet and permit imprinting manufacturer’s information. Sugar 
coating provides a combination of insulation, taste masking, smoothing the tablet 
core, coloring and modified. 
  The disadvantages of sugar coating are time, expertise required in the 
coating process, increase in size, weight and shipping costs. 
 Sugar coating process involves five separate operations: 
I. SEALING/WATER PROOFING: Provides a moisture barrier and harden the 
tablet surface. 
II. SUB COATING: Causes a rapid buildup to round off the tablet edges. 
III. GROSSING/SMOOTHING: Smoothes out the sub coated surface and 
increases the tablet size to predetermine dimension. 
IV. COLORING: Gives the tablet its color and finished size. 
V. POLISHING: Produces the characteristics gloss. 
2. FILM COATING  
Film coating is more favored over sugar coating. Now days, sugar coating 
is replaced with film coating, because the sugar coating process was a skilled 
manipulative process and could last for even five days. The operator must be 
highly skilled for such coating. Hence film coating is preferred over sugar 
coating.19 
a.BASIC PRINCIPLES INVOLVED IN FILM COATING 
1. Insulation which influences the release pattern as little as possible and does 
not markedly change the appearance. 
2. Modified release with specific requirement and release mechanism adapted 
to body function in the digestive tract. 
3. Color coating which provides insulation or is combined with modified 
release coating. 
b. MATERIALS USED IN FILM COATING 
I. Film formers, which may be enteric or non-enteric 
II. Solvents 
III. Plasticizers 
IV. Colorants 
V. Opaquant-Extenders 
 VI. Miscellaneous coating solution components 
c. FILM DEFECTS  
 Include sticking and picking, roughness, orange-peel effect, bridging and 
filling, blistering, hazing/dull film, color variation, cracking. 
3. ENTERIC COATING 
 Enteric coated tablets are tablets with a coating that resist dissolution or 
disruption in the stomach but not in the intestine, thereby allowing for tablet transit 
through the stomach in favor of tablet disintegration and dissolution and 
absorption from the intestine. 
 The materials used in enteric coating are shellac, hydroxy propyl methyl 
cellulose phthalate, poly vinyl phthalate and cellulose acetate phthalate. 
4. SPECIALIZED COATING    : It includes Compression coating, Electrostatic 
coating, Dip coating, Vacuum film coating.20 
1.4.11. EVALUATIONOFTABLET  
     Tablets when formulated may undergo physical and chemical changes, which 
may alter their bioavailability. Therefore, the tablets are to be evaluated before 
dispensing to ensure their stability and bioavailability throughout their shelf life. 
Evaluation of tablets can be carried out by the following test. 
A. CHARACTERISTICS OF GRANULES 
 Flow Ability 
 Compressibility 
 Bulk density  
 Tapped density 
B. COMPRESSED TABLET CHARACTERISTICS 
UNOFFICIAL TESTS 
• Tablet appearance 
• Organoleptic parameters 
 • Identification markings on the tablets 
• Size and shape of the tablet 
• Thickness of the tablet 
• Hardness of the tablet 
• Friability of the tablet 
OFFICIAL TESTS (According to IP) 
• Weight variation test 
• Content uniformity 
• Disintegration test 
• Dissolution test 
 
 
1.5. STABILITY STUDIES AS PER ICH GUIDELINES  
 Stability is defined as the capacity of a drug substance or drug product to 
remain within the established specifications to maintain its identity, strength, 
quality and purity throughout the retest or expiration dating period. 
The objective of stability study is to determine the shelf life, namely the 
time period of storage at a specified condition within which the drug product still 
meets its established specifications. 
 Stability is an essential factor of quality, safety and efficacy of a drug 
product. A drug product, which is not of sufficient stability, can result in changes 
in physical (like hardness, dissolution rate, phase separation etc) as well as 
chemical characteristics (formation of high risk decomposition substance.The 
chemical stability of drug is of great importance since it becomes less effective as 
it undergoes degradation. Also drug decomposition may yield toxic  by  products 
that are harmful to the patient. Microbiological instability of a sterile drug product 
could also be hazard. 
 II.AIM AND OBJECTIVE OF WORK 
 
The present study aims at developing a clarithromycin immediate release 
tablet formulation for the effective treatment of respiratory tract infections. 
  Clarithromycin is macrolide antibiotic produced by various strains of 
streptomyces. The mechanism of action of clarithromycin is inhibition of bacterial 
protein biosynthesis. Clarithromycin is acid stable and it is rapidly absorbed from 
the gastrointestinal tract after oral administration. The plasma half-life of 
clarithromycin is 2-3 hours. The usual duration of treatment of clarithromycin is 6 
to 14 days. Clarithromycin is economically beneficial than all other macrolide 
antibiotics. 
 The main objective of this study was to  
i) To formulate clarithromycin immediate release film coated tablet. 
ii) To evaluate the formulated tablets as per requirements of standards. 
iii) To optimize the trial batch by 32  full factorial design study. 
iv) To evaluate the optimized  batches. 
v) To determine the best batch by dissolution studies. 
vi) Drug release profile was compared with innovator product. 
vii) To calculate the similarity and dissimilarity factor for both drug release 
profile and innovator drug product. 
viii) To perform stability studies for the optimized batch for 3 months at 
40oC/75%  RH. 
 
 
 
                                 PLAN OF WORK  
 
A) Literature review 
B) Drug profile 
C) Excipient profile 
D) Innovator product specification 
E) Preformulation studies 
a) Evaluation of API 
 Description 
 Solubility 
 pH 
 Melting point 
 Chemical nature 
 Hygroscopicity 
 Particle size distribution 
 Loss on drying 
b) Drug excipient compatibility studies 
 Physical observation 
 FT-IR studies 
F) Selection of excipients by finger print method 
G) Formulation of uncoated clarithromycin immediate release tablets by 
wet granulation method. 
H) Evaluation of the granules. 
I) Evaluation of physical parameters for compressed tablet.  
i. Weight variation 
ii. Thickness 
iii. Hardness 
iv. Friability 
 v. Disintegration  
vi. Determination of drug content 
J) In vitro dissolution studies. 
K) Coating of the formulated clarithromycin immediate release tablets. 
L) Evaluation of the coated tablets. 
M) Optimization of the trial batch by full factorial design. 
N) Evaluation of the optimized batches.  
O) Comparison of the drug release for optimized batch and innovator 
product. 
P) Stability studies of the optimized formulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                          III. LITERATURE REVIEW 
 
 Saleki-Gerhardt et al., US patent 1999 jul.6/5, 919, 48929 Provided a 
process for the aqueous granulation of a macrolide antibiotic which comprises 
mixing a macrolide and a carbomer, wetting  the mixture with water and blending 
the mixture to allow formulation of a macrolide antibiotic-carbomer granule. 
 
 Wadhwa et.al., US patent Nov.4,2003/US 6,642,276 B230 Related to an 
controlled release macrolide pharmaceutical formulation. It gives a information 
about method of preparation, isolating and characterizing soluble and stable citrate 
salt of macrolides and use in all solid dosage forms of macrolides. 
 
 Margret  Chandra, et al.,31  Developed a  mucoadhesive tablets   of 
clarithromycin which were designed to prolong the gastric residence time after oral 
administration. Clarithromycin is in a class of medications called macrolide 
antibiotics. It works by stopping the growth of bacteria. matrix  tablets of 
clarithromycin were formulated using four mucoadhesive polymers namely 
carbopol 974P, HPMC K15M and HPMC K4M carried out studies for weight 
variation, thickness, hardness, content uniformity, swelling index, mucoadhesive 
force and in vitro drug release. Formulation of F9 and F12 which were formulated 
by using polymers, HPMC K14M, HPMC K15M and carbopol 974P provided 
controlled release of clarithromycin over the period of 12 hrs. The cumulative % of 
drug release of formulation F9 and F12 were 93.16 and 96.82 respectively. The 
stability studies showed that there was no significant change in adhesive strength, 
invitro release when stored at room temperature, 40oC, and 2-8oC for a period of 
30 days. 
 Rahul Suture. et al.,32  Developed  a   drug delivery systems to gastro 
intestinal tract for treatment of H.pylori  induced peptic and duodenal ulcers, in the 
present study an attempt has been made to develop and evaluate hydro dynamically 
balanced matrix tablets of  
 clarithromycin which were prepared by using hydroxypropyl    methyl 
cellulose  K 4M (HPMC K4M),  hydroxypropyl   methylcellulose  K 15M      
(HPMC 15 M) and chitosan with NaHCO3 as gas forming  agent. These matrix 
tablets were evaluated for their physiochemical properties, buoyancy and tablet 
density. Effect of hardness on matrix revealed that increase in hardness affects 
 buoyancy lag time due to reduction in porosity of compact mass. The release rate 
determined on 0.1N HCl (pH1.2) showed controlled release of drug following non-
Fickian mechanism 
 N.B. Santha Sheela. et.al.,33 Formulated  a floating sustained release 
tablets of clarithromycin, by using a combination of hydrophilic polymers 
(different grades of hydroxypropyl methylcellulose), kollidon SR and an 
effervescent substance (sodium bicarbonate). The formulation were evaluated to 
study the effect of sodium bicarbonate concentration on the floating lag time, total 
duration of floating, invitro dissolution release profile and the effect of different 
fillers and ethyl cellulose concentration on the release profile of drug. It was found 
that among all the formulations, formulation F4 (HPMC K15M, Avicel 102 PH and 
sodium bicarbonate) was found to be the optimum formulation as it had good 
swelling property, floating time and drug releases. The drug release of optimized 
formulation was found to follow zero order, Higuchi and  Korsemeyer-peppas 
kinetic models. 
 Sanjay S. Patel, et.al.,34 Developed a floating matrix tablets designed to 
prolong the gastric residence time after oral administration, at a particular site and 
controlling the release of drug especially useful for achieving controlled plasma 
level as well as improving bioavailability. With this objective, floating dosage form 
containing clarithromycin as drug was designed for the treatment of Helicobactor 
pylori. Tablets containing hydroxy propyl methyl cellulose (HPMC), drug and 
different additives were compressed using wet granulation and D-optimal design 
technique. The study shows that tablet composition and mechanical strength have 
great influence on the floating properties and drug release. Incorporation of gas – 
generating agent together with polymer improved drug release, besides optimal 
floating (floating lag time <30 seconds; total floating time 10 hours). The drug 
release was sufficiently sustained (more than 8 hours) and anomalous diffusion as 
well as zero-order was confirmed. Optimization of the evaluating parameters with 
“design expert” software was employed to get final optimized formulation. The 
optimized formulation was obtained using 62.5% clarithromycin, 4.95% HPMC 
K15M, 18.09% HPMC k4M, 12.96%  sodium bicarbonate which gave floating lag 
time  <30 seconds with a total floating time  > 10 hours, invitro release profile very 
near to the target in vitro release profile and follows anomalous diffusion as well as 
zero order pattern of release. 
 
  Balkrushna K. Patel. et.al., 35 Described the preparation of Clarithromycin 
hydrophilic matrix tablets by direct compression technique followed by invitro 
floating characterization statistically. The floating hydrophilic matrix tablets 
prepared by using different grades of polymer (HPMC) of varying concentrations, 
different concentration of sodium bicarbonate and varying ratios of MCC. Floating 
properties such as FLT, TFT, and Swelling index. Tablet hardness had found to be 
affecting on floating behavior. Hydrophilic matrix floating tablets of clarithromycin 
were developed to increase the gastric residence time, which leads to increased 
bioavailability by giving sufficient time to release the drug in Gastro Intestinal 
tract. 
 Shah S.H. et.al.,36 Developed a rate-controlled oral drug delivery systems 
to overcome physiological adversities, such as short gastric residence times (GRT) 
and unpredictable gastric emptying times (GET). It is known that differences in 
gastric physiology, such as, gastric pH, and motility exhibit both intra-as well as 
inter-subject variability demonstrating significant impact on gastric retention time 
and drug delivery behavior. This triggered the attention towards formulation of 
stomach specific (gastro retentive) dosage forms. This dosage forms will be very 
much useful to deliver ‘narrow absorption window’ drugs. Several approaches are 
currently utilized in the prolongation of the GRT, including floating drug delivery 
systems (FDDS), swelling and expanding systems, polymeric bioadhesive systems, 
high-density systems, modified-shape systems and other delayed gastric emptying 
devices. In this review, current & recent developments of stomach specific FDDS 
are discussed. 
 Aphale Sanjivini. et.al., 37 Developed hollow floating microspheres of 
clarithromycin for gastro retention using Eudragit polymers prepared by emulsion 
solvent diffusion method. Eudragit S 100, RS 100, RL 100, L 100 and L 100 55 
were used to prepare hollow microspheres. A drug – excipient compatibility study 
was performed using FTIR. The microspheres were characterized for shape and 
surface morphology by scanning electron microscopy. They were evaluated for 
particle size, flow properties, bulk density, % drug entrapment efficiency, floating 
properties and in-vitro drug release. The residual solvent content was determined 
after varying the stirring time. Drug to polymer ratio was varied from 1: 1 to 1: 3 
and its effect on particle size and drug release was studied. The microspheres 
exhibited round shape, porous surface, prolonged drug release and buoyancy for 
more than eight hours. As the drug to polymer ratio is increased. The particle size 
increased and the drug release rate decreased. 
  P.K. Gupta. et. al., 38 Summarized the results of in vitro and invivo studies 
conducted to evaluate the feasibility of developing an intramuscular (i.m.) 
formulation of  clarithromycin by encapsulating in a biodegradable polymer, 
poly(lactic acid) (PLA). 
 Drug/PLA microspheres were prepared by solvent evaporation and 
recovered by filtration or spray-drying. Variations in processing parameters, e.g., 
polymer concentration in the dispersed phase, type of continuous phase and the 
recovery process, did not appreciably alter microsphere particle shape, size or drug 
loading. In 0.05 M phosphate buffer (pH 7.4, at 37°C), compared to the dissolution 
of bulk drug, the microsphere formulations demonstrated good sustained release 
properties. In a preliminary in vivo study, 10 mg/kg drug was administered i.m. to 
groups of three dogs as a suspension of bulk drug or via PLA microspheres. Blood 
samples were collected over time to monitor drug and creatinine phosphokinase 
(CPK) concentrations. Both groups demonstrated drug concentrations ≥ 1 μg/ml for 
about 4 days after dosing. Also, the serum CPK concentrations in both groups were 
low, and compared well with those observed following the i.m. administration of 
placebo microspheres. The animals receiving drug/PLA microspheres demonstrated 
minor swelling at the site of injection which lasted for 12–24 h; however, the bulk 
drug treatment group exhibited much greater swelling lasting for 2–3 days. Since 
these observations do not correlate with serum CPK levels, alternative quantitative 
models are required to conclusively evaluate the potentials of microsphere 
formulations for the i.m. delivery of painful/irritating compounds like 
clarithromycin. 
 Chudiwal P.D. et.al., 39  Developed an optimized gastro retentive drug 
delivery system (GRDDS) of clarithromycin floating microspheres by the 
optimization technique. The clarithromycin microspheres were prepared by non 
aqueous solvent evaporation method using different grades of hydroxyl propyl 
methylcellulose (HPMC) such as HPMC 15M (15cps), HPMC K4M (4000cps), 
HPMC 100LV (100cps) and ethyl cellulose (EC). The prepared microspheres were 
characterized by polymer compatibility, percentage yield, buoyancy percentage, 
drug entrapment efficiency and in vitro drug release. An optimized formulation 
investigated for morphology and particle size analysis by scanning electron 
microscopy. A 32 factorial design was employed in formulating the GRDDS with 
different viscosity grades of HPMC (X1) and polymer-to polymer ratio Ethyl 
cellulose: HPMC (X2) as independent variables. Four dependent variables were 
percentage of yield, drug entrapment efficiency, buoyancy percentage and 
 percentage of cumulative drug release of microspheres after 12h (R12h). The main 
effect and interaction terms were quantitatively evaluated using a mathematical 
model. Regression analysis and numerical optimization were performed to identify 
the best formulation. The predicted values agreed well with the experimental 
values, and the results demonstrate the feasibility of the model in the development 
of GRDDS. 
 M Khalid Khan.et.al., 40  Assessed the bioequivalence of tablets 
formulations of Clarithromycin 500mg each of test and reference products. A 
single post oral dose of each formulation was given to 14 male healthy volunteers. 
The study was conducted phase 1, open-label, randomized, complete two- way 
crossover designed with 7 days wash out period. The plasma concentration of 
clarithromycin was quantified by validated microbiological assay method. The 
precision of the method was evaluated using calibrated 14-hydroxy clarithromycin 
concentration was detected semi quantitatively as equivalent of clarithromycin /ml. 
The peak plasma concentrations of (3.63±0.80 ug/ml) and (3.31±0.35 ug/ml) was 
attained in about 1.42 hours and 1.49 hours for both test and reference 
Clarithromycin tablets respectively. The mean ± SD values for total area under the 
curve (AUC) were 22.07±4.90 and 20.16±2.35 h.mg/L for both test and reference 
tablets respectively. This study indicated that the differences in all the 
bioequivalence parameters for test and reference Clarithromycin formulations are 
statistically non-significant. Hence, both formulations are considered bioequivalent. 
 Muralidhar Nama. et.al.,41 Developed the hydro dynamically balanced 
delivery system of Clarithromycin (CLA) which, after oral administration should 
have the ability to prolong gastric residence time with the desired in vitro release 
profile for the localized action in the stomach, in the treatment of Helicobacter 
pylori (H.pylori) mediated peptic ulcer. By applying wet granulation technique, 
floating tablets of Clarithromycin were prepared. The proportion of sodium 
bicarbonate was varied to get the least possible lag time, also the polymer part 
varied to get the desired release. In vivo radiographic studies were performed with 
Barium sulphate loaded formulation to justify the increased gastric residence time 
of the dosage form in the stomach, based on the floating principle. The formulation 
developed using 66.2% Clarithromycin, 12% HPMC K4M polymer, 8% sodium 
bicarbonate gave floating lag time less than 3 min with a floating time of 12 h, and 
an in vitro release profile very near to the desired release. X-ray studies showed the 
enhanced gastric residence time of the tablet to 220± 30 min. The mechanism of 
release of Clarithromycin from the floating tablets is anomalous diffusion transport 
 and follows zero order kinetics. In vivo radiographic studies suggest that the tablet 
has increased gastric residence time for the effective localized action of the 
antibiotic (Clarithromycin) in the treatment of H.pylori mediated peptic ulcer. 
 Pradeep Kisan Nimase. et.al.,42 Developed a  multiple-unit floating beads 
of clarithromycin from sodium alginate solution containing hydroxyl propyl 
methylcellulose (K100M) and sunflower oil using the technique of three variables 
at three levels (33) factorial design and twenty-seven possible batches were 
prepared. These beads were evaluated for entrapment efficiency, drug loading, 
buoyancy and in vitro drug release. 
 All formulations showed floating lag time below 2 minutes and showed 
total floating duration more than 10 hours. The result of in-vitro dissolution studies 
revealed that the formulation F14 was showing sustained release pattern of 
clarithromycin. The release rate, entrapment efficiency, drug loading and buoyancy 
was greater with formulation containing 2 percent sodium alginate solution and 5 
percent calcium chloride solution along with 5 ml sunflower oil. 
 Nirav s sheth. et.al.,43 Designed a floating drug delivery to prolong  the 
gastric residence time after oral administration at a particular site. It is useful for 
achieving controlled plasma level as well as improving bioavailability. With this 
objective, floating dosage form containing clarithromycin as drug was designed for 
the treatment of Helicobacter pylori infection. Tablets containing hydroxyl propyl 
methylcellulose (HPMC) drug and different additives were compressed using wet 
granulation. The study showed that tablet composition and mechanical strength 
have great influence on the floating properties and drug release. Incorporation of 
gas-generating agent together with polymer improved drug release, besides optimal 
floating lag time less than 30 sec, total floating time less than 6 hrs. The optimized 
formulation was obtained using 150mg of HPMC K4M gave floating lag time less 
than 30 sec with a total floating time greater than 6 hrs. 
 Paruvathanahalli Siddalingam rajinithkanth.et.al., 44 Developed a stomach-
specific drug delivery system for controlled release of clarithromycin for 
eradication of Helicobacter pylori (H. pylori). Floating-bioadhesive microspheres 
of clarithromycin (FBMC) were prepared by emulsification-solvent evaporation 
method using ethylcellulose as matrix polymer and Carbopol 934P as 
mucoadhesive polymer. The prepared microspheres were subjected to evaluation 
for particle size, incorporation efficiency, in vitro buoyancy, in vitro mucoadhesion 
and in vitro drug release characteristics. The prepared microspheres showed a 
strong mucoadhesive property with good buoyancy. The formulation variables like 
 polymer concentration and drug concentration influenced the in vitro drug release 
significantly in simulated gastric fluid (pH. 2.0). The in vivo H. pylori clearance 
efficiency of prepared FBMC in reference to clarithromycin suspension following 
repeated oral administration to H. pylori infected Mongolian gerbils was examined 
by polymerase chain reaction (PCR) technique and by a microbial culture method. 
The FBMC showed a significant anti-H. pylori effect in the in vivo gerbil model. It 
was also noted that the required amount of clarithromycin for eradication of H. 
pylori was significantly less in FBMC than from corresponding clarithromycin 
suspension. The results further substantiated that FBMC improved the gastric 
stability of clarithromycin (due to entrapment within the microsphere) and 
eradicated H. pylori from the  sgastrointestinal tract more effectively than 
clarithromycin suspension because of the prolonged gastrointestinal residence time 
of the formulation. 
 Mark A. Jacobson. et. al.,45 Developed a  prophylaxis for AIDS-related 
disseminated Mycobacterium avium complex (dMAC) infection. Immediate-
release (IR) clarithromycin tablets are dosed at 500 mg bid for these indications. A 
new extended-release (ER) tablet of clarithromycin has been developed and 
approved at a dosing interval of once every 24 hours for treatment of respiratory 
tract bacterial infections. However, the pharmacokinetics of clarithromycin ER in 
AIDS patients with or at risk for dMAC has not been previously investigated.  
They conducted a randomized, crossover trial in which 14 AIDS patients received 
clarithromycin ER, 1000 mg once daily, and clarithromycin IR, 500 mg bid, each 
for 1 week, with pharmacokinetic sampling at the end of each week. The mean of 
the individual AUC ratios for clarithromycin ER vs. IR was 1.09 (90% CI, 0.94–
1.24). Adverse events were no more severe or frequent with clarithromycin ER 
than IR. Clarithromycin ER is a once-daily regimen that is as well tolerated as 
standard bid IR clarithromycin dosing and has average bioequivalence to the IR 
formulation in patients with AIDS. 
 Eraha.et.al., 46  Explained  a increased antibiotic chemical stability 
resulting from gastric pH changes induced by co administration of omeprazole. The 
chemical stability of clarithromycin, amoxycillin and metronidazole was 
investigated in aqueous solutions and in human gastric juice collected before and 
after a 7-day course of omeprazole. Amoxycillin, clarithromycin and metronidazole 
were prepared in buffered aqueous solutions of pH 1.0 to 8.0 and in gastric juice of 
pH 2.0 and 7.0.   The gastric juice samples were obtained from fasted H. pylori-
negative volunteers before and after they had received a 7-day course of 
 omeprazole. All the samples were incubated at 37°C and analyzed at intervals by 
HPLC. Amoxycillin, clarithromycin and metronidazole were stable in aqueous 
solutions of pH 4.0–7.0, pH 5.0–8.0 and pH 2.0–7.0, respectively. At pH 2.0, the 
degradation half-lives were 19.0 ± 0.2 h, 1.3 ± 0.05 h and 2200 ± 1100 h, 
respectively. In gastric juice samples of pH 2.0, the degradation half-lives were  
15.2 ± 0.3 h, 1.0 ± 0.04 h and ³800 h, respectively. The half-lives of the drugs in the 
gastric juice samples of pH 7.0 were all >68 h. The co-administration of 
omeprazole with amoxycillin or clarithromycin is likely to increase the chemical 
stability of amoxycillin and clarithromycin in gastric juice. Clarithromycin 
degrades rapidly at normal gastric pH (1.0–2.0) but amoxicillin and metronidazole 
are sufficiently stable at this pH to maintain an antibacterial concentration in the 
stomach. 
 Liandong Hu. et.al.,47 Developed and validated a method to prepare 
clarithromycin (CLM) microcapsules to mask the bitter taste and provide effective 
treatment, and evaluate the quality of microcapsules in detail, especially the in vitro 
and in vivo pharmacokinetics behavior. CLM microcapsules were prepared using 
ethyl cellulose as matrix material by an emulsion solvent diffusion method. The 
physicochemical property, in vitro release study, sensory test and stability test were 
evaluated. Self-made CLM dry suspension or conventional tablets containing 250 
mg of CLM were orally administered with 250 mL of water. The plasma 
concentration was determined and the pharmacokinetic parameters were calculated 
by non-compartmental methods. Stable microcapsules could be prepared using 
ethyl cellulose as matrix material.    The quality evaluation of prepared 
microcapsules was qualified, and the pharmacokinetic parameters of dry 
suspensions and conventional tablets were as following. Cmax were 1.32±0.62 and 
1.40±0.58 μg ml-1；Tmax were 3.51±0.54 and 2.01±0.42 h；AUC were 
7.65±2.54 and 7.12±2.10 μg h ml-1. The preparation method is easy and applicable. 
The self-made CLM dry suspension containing microcapsules sufficiently alleviate 
the bitterness of commercial CLM dry suspension, but not decrease the 
bioavailability and have better effect for delaying drug release in healthy 
volunteers. 
 Anish Kumar Gupta. et.al., 48 Developed a controlled release system 
targeting antibiotic delivery to the stomach. The hydrogels were synthesized by 
using chitosan, poly (acrylic acid) and poly (vinyl pyrrolidone) polymers 
crosslinked with glutaraldehyde and N,N'-methylenebisacrylamide. 
Interpenetrating polymeric network (IPN) hydrogels were prepared by varying the 
 concentration of crosslinking agent (glutaraldehyde). The amount of chitosan, poly 
(acrylic acid), poly (vinyl pyrrolidone) and N,N'-methylene bis acrylamide were 
kept constant in all formulations. The effect of glutaraldehyde concentration on the 
swelling and release characteristics were evaluated. Modalities used to assess the 
most optimal hydrogel formulation included high liquid chromatography, FTIR 
analysis, differential scanning calorimetry, swelling studies, in vitro drug release 
study, mucoadhesive study and scanning electron microscopy. The result showed 
that IPN hydrogels were greater in swelling, more mucoadhesive and released more 
drugs at lower pH values. Thus, it is believed that the antibiotic concentration in the 
stomach might be sustained through this formulation. 
 Mark H. Gotfried. et.al.,49 Developed the steady-state concentrations of 
clarithromycin in plasma were compared with concomitant concentrations in 
epithelial lining fluid (ELF) and alveolar macrophages (AM) obtained from 
intrapulmonary samples during bronchoscopy and bronchoalveolar lavage 
(BAL).Concentrations of the major metabolite, 14 hydroxy clarithromycin, were 
also determined in plasma and AM. Forty-two healthy, non-smoking adult subjects 
(age: 18–54 years; 19 females, 23 males) received oral clarithromycin extended-
release formulation (1000 mg once daily for five consecutive days). Bronchoscopy 
and BAL were carried out once in each subject at either 3, 6, 9, 12, 24 or 48 h after 
the last administered dose of clarithromycin. In addition, three subjects who did not 
take clarithromycin served as controls and underwent bronchoscopy at 0 hr.   Drug 
concentrations in plasma, ELF, and AM were determined by high-performance 
liquid chromatography. Clarithromycin was extensively concentrated in ELF [range 
of mean (±S.D.) concentrations: 6.38 ± 3.92 to 11.50 ± 6.65 mg/L] and AM (127.0 
± 61.5 to 573.8 ± 309.3 mg/L) than simultaneous plasma concentration (0.75 ± 0.31 
to 2.22 ± 0.72 mg/L). The ranges of mean (±S.D.) concentrations of 14-
hydroxyclarithromycin in plasma and AM were 0.52 ± 0.29 to 0.80 ± 0.31 mg/L 
and 22.1 ± 13.5 to 49.5 ± 16.2 mg/L, respectively. Conclusions: Once-daily dosing 
of extended-release formulation clarithromycin 1000 mg produced significantly             
(P < 0.05) higher steady-state concentrations of clarithromycin in ELF (2–14 times) 
and AM (50–700 times) compared to simultaneous plasma concentrations 
throughout the 24 h period after drug administration. The 14-hydroxy metabolite of 
clarithromycin achieved significantly (P < 0.05) higher steady-state concentrations 
in   AM  (18–180 times) compared with concurrent plasma concentrations. 
 GK.Tripathi.et.al., 50 Developed a pH-sensitive controlled release 
formulation of clarithromycin in oil-entrapped calcium pectinate microgel bead. 
 Pectin-based oil-entrapped microgel beads were prepared by ionic gelation 
technique. The gel beads were formed instantly after adding the liquid formulation 
mixture drop wise into calcium chloride solution. The beads were optimized by 
coating with ethyl cellulose solution and then evaluated for their diameter, floating 
lag time, encapsulation efficiency and drug release. Particle size, encapsulation 
efficiency and buoyancy were significantly affected by the concentration of the 
polymer and calcium chloride. The formulation exhibited sustained release profile 
and was best fitted to the Peppas model with   n < 0.45. Ethyl cellulose-coated 
formulation batch, C16, was the most suitable controlled formulation with drug 
release of 65 ± 2.61 % in 8 h. An ethyl cellulose-coated formulation with potential 
for sustained delivery of clarithromycin in the acidic region of the gastrointestinal 
tract was successfully developed. 
 M. Lohitnavy. et.al., 51 Assessed a  average bioequivalence of two 
immediate released tablet formulations of 500-mg clarithromycin tablets in 24 
healthy Thai male volunteers. In a randomized, single dose, fasting state, two-
period, crossover study design with a 1-week washout period, each subject received 
a 500-mg clarithromycin tablet. Plasma samples were collected over a 24-hour 
period after oral administration and were analyzed by using a validated method 
using high performance liquid chromatography with electrochemical detection. 
Pharmacokinetic parameters were determined by using noncompartmental analysis. 
The time to reach the maximal concentration (tmax, h), the peak concentration 
(Cmax, ng/mL), and the area under the curve (AUC0 − ∞, ng.h/mL) of the 
Reference and Test formulations were 2.0 ± 0.8 vs. 2.2 ± 0.9, 2793 ± 1338 vs. 2642 
± 1344, and 17912 ± 7360 vs. 17660 ± 7992, respectively. Relative bioavailability 
was 0.99. The 90% confidence interval of Cmax and AUC0 − ∞ were 82.6–112.1% 
and 84.7–112.0%. Bioequivalence between the Test and Reference formulation can 
be concluded. 
 Suman Ramteke. et.al., 52  Prepared and evaluated the oral mucoadhesive 
sustained release nanoparticles of clarithromycin in order to improve patient 
compliance by simplifying its administration, improving its therapeutic effect and 
reducing its dose related side effect. Clarithromycin containing gliadin 
nanoparticles were prepared by desolvation method using pluronic F-68 as a 
stabilizing agent. The results showed that this method is reproducible, very easy 
and led to the efficient entrapment of drug as well as formation of spherical 
particles ranging from 250-500 nm. Some process variables like effect of gliadin 
concentration and effect of surfactant were also evaluated with respect to their % 
 drug entrapment and % yields. The maximum % drug entrapment and % yield were 
about 73 and 88%, respectively. The sustained release behavior of gliadin 
nanoparticles were evaluated both in phosphate buffer saline (pH 7.4) and 
simulated gastric fluid (pH 1.2), respectively at 37±1oC.         Their mucoadhesive 
properties were determined by in vivo and in vitro methods. The shelf life of 
prepared nanoparticles was determined by storage at various temperatures while 
assessed in simulated gastric fluid (pH1.2) with and without enzyme. 
 Md. Nehal Siddiqui, et.al.,53 Developed the fast dissolving tablet (FDT) 
with improved patient compliance and convenience. FDTs are solid dosage forms 
which dissolve rapidly in saliva without chewing and additional water. FDTs 
overcome the disadvantages of conventional dosage form especially dysphagia 
(difficulty in swallowing) in pediatric and geriatric patients. 
 This review includes ideal properties, characteristics, challenges in 
formulation, suitability of drug candidates, various technologies developed for 
FDT, patented technologies, evaluation methods and various marketed products. 
 Pradeep Kisan Nimase. et.al.,54 Developed a Multiple-unit floating beads 
of             clarithromycin from sodium alginate solution containing hydroxypropyl 
methylcellulose (K100M) and sunflower oil using the technique of three variables 
at three levels (33) factorial design and twenty-seven possible batches were 
prepared. These beads were evaluated for entrapment efficiency, drug loading, 
buoyancy and in vitro drug release. All formulations showed floating lag time 
below 2 minutes and showed total floating duration more than 10 hours. The result 
of in-vitro dissolution studies revealed that the formulation F14 was showing 
sustained release pattern of clarithromycin. The release rate, entrapment efficiency, 
drug loading and buoyancy was greater with formulation containing 2 percent 
sodium alginate solution and 5 percent calcium chloride solution along with 5 ml 
sunflower oil. 
 Shashikant D. Barthate.  et.al.,55  Designed a floating matrix tablets to 
prolong the gastric residence time after oral administration, at a particular site and 
controlling the release of drug especially useful for achieving controlled plasma 
level as well as improving bioavailability. With this objective, controlled release 
floating tablets of clarithromycin were formulated by using D-optimal mixture 
design for the treatment of Helicobacter pylori. The amount of HPMC K4M: 
HPMC K100LV in 1:1 ratio (X1), amount of Na-CMC (X2) and amount of sodium 
bicarbonate (X3) were selected as independent variables and percentage drug 
release at 3 h (Y1), percentage drug release at 6h(Y2), percentage drug release at 
 12h (Y3) and total floating lag time (Y4) as dependent variables. Tablets containing 
HPMC K4M and HPMC K100LV, drug and different additives were prepared by 
wet granulation. The tablet composition and mechanical strength have great 
influence on the floating properties and drug release. Optimization of the 
evaluating parameters with Design expert software was employed to generate 
optimized formulation and criteria of desirability was employed. The optimized 
formulation was obtained with HPMC K4M: HPMC K100LV in 1:1 ratio (125.428 
mg), Na-CMC (40.256 mg) and sodium bicarbonate (34.316 mg). The in vitro 
release data showed that the drug release follows zero-order release kinetics. 
 Bathini Sree Tejaswi.  et.al.,56 Developed a stomach-specific drug delivery 
system for controlled release of clarithromycin for eradication of Helicobacter 
pylori (H. pylori). Floating Microspheres of clarithromycin (FMC) were prepared 
by Solvent Evaporation Technique using ethyl cellulose as a polymer. The prepared 
microspheres were subjectedto evaluation for particle size, incorporation 
efficiency, in vitro buoyancy, in vitro drug release characteristics and stability 
studies. These microspheres showed good buoyancy. The formulation variables like 
polymer concentration and drug concentration influenced the in vitro drug release 
significantly in simulated gastric fluid (pH 2.0). It was also noted that the required 
amount of clarithromycin for eradication of H. pylori was significantly less in FMC 
than from corresponding clarithromycin suspension. About 82% of the prepared 
microspheres floated in hydrochloric acid buffer solution for 12h. 71% of the 
clarithromycin contained in the microspheres were released within 12 h in a 
sustained manner. These results suggest that FMC will be a promising drug 
delivery system for the treatment of H. pylori infection. 
 Venkateswaramurthy N. et.al., 57  Designed a  mucoadhesive microspheres 
containing Clarithromycin as an anti-H. pylori agent to deliver the drug specifically 
to mucus layer where H.pylori resides and evaluate the effectiveness of the 
mucoadhesive microspheres for H. pylori eradicationtherapy. Microspheres were 
prepared by using Eudragit RL100 as matrix and Carbopol 974P and Hydroxy 
propyl methyl cellulose K4M as mucoadhesive polymer. The microspheres  
prepared by emulsion solvent evaporation technique. The prepared microspheres 
were evaluated with respect to the particle size, production yield, encapsulation 
efficiency, shape and surface properties, mucoadhesive property, In-vitro drug 
release and suitability for anti Helicobactor pylori effect. The preliminary results 
show great promise for this delivery strategy in the treatment of H. Pylori infection    
                              IV. MATERIALS AND METHODS 
                            4.1. LIST OF MATERIALS USED 
Table No. 3: List of materials used 
S. No. Materials Manufacturers/Suppliers 
1 Clarithromycin Anuh pharma Pvt.Ltd. 
2 Croscarmellose sodium Signet chemicals pvt.,Ltd 
3 Colloidal silicon dioxide Cabor sanmar Ltd 
4 Ethyl cellulose The dow chemical company 
5 Ethyl vanillin Firemenich, Switzerland. 
6 Hydroxy propyl cellulose Aqualon 
7 Pregelatinised starch DMV Fonterra excipients,USA. 
8 Microcrystalline cellulose PH 
101 
Signet chemicals pvt.,Ltd 
9 Microcrystalline cellulose PH 
102 
Weiming Pharmaceuticals 
10 Propylene glycol Clariant  
11 Povidone IP (K-30) Nanberg India co. 
12 Isopropyl alcohol Deepak Fertilizers 
13 Magnesium stearate Vijlak Pharma 
14 Talc Luzanac pharma 
15 Titanium dioxide BASF 
16 Qunoline yellow lake Satyasta chemicals, kanpur 
 
                                   4.2. DRUG PROFILE 
 CLARITHROMYCIN 64 : 
Structure                                    :                                                                                           
    
 
Molecular formula  :  C38H69NO13  
Molecular weight  : 748.95   
Chemical name  : 6-O-Methyl erythromycin A.  
Therapeutic category : Semi synthetic Macrolide Antibiotic. 
Active metabolite                  :  Clarithromycin,14-hydroxyclarithromycin. 
Description   : White  to off-white,  Non-hygroscopic crystalline 
powder.  
Melting point   : 217-220oC 
Solubility                                : Practically insoluble in water,Soluble in acetone, 
Slightly soluble in methanol, ethanol and acetonitrile. 
 Dos                                          : 250-500 mg BD 7-14 days  
Plasma half-life                      :    2-3 hours 
Steady state peak plasma concentrations : Attained within 3-4 days. 
Elimination half-life              :    3-7 hours for clarithromycin, 5-9 hours for 14-
OH   clarithromycin. 
Absolute bioavailability        :  Approx.50%  
clearance                                 :  Approximates normal GFR.  
Shelf life                                  : 36 months 
Impurities 65                            :  Clarithromycin N-oxide 
                                                     N-Desmethyl clarithromycin (EP Impurity D) 
                                                     N-Desmethyl erythromycin A 
                                                     N-Formyl clarithromycin (EP Impurity H) 
 
PHARMACOLOGY 9,10,11,12,60,61,62  
MECHANISM OF ACTION: 
Macrolides are protein synthesis inhibitors. The mechanism of action of 
macrolides is inhibition of bacterial protein biosynthesis, the drugs act by binding 
to cell membranes and causing changes in protein function and they are thought to 
do this by preventing peptidyltransferase from adding the peptidyl attached to t-
RNA to the next amino acidas well as inhibiting ribosomal translocation. Another 
potential mechanism is premature dissociation of the peptidyl-tRNA from the 
ribosome. 
Macrolide antibiotics do so by binding reversibly to the P site on the 
subunit 50S of the bacterial ribosome. Macrolides inhibit the translocation of the 
growing peptide chain from A site to P site. Hence A site is not available for 
binding of next aminoacid (brought by t-RNA).This action is mainly 
 bacteriostatic, but can also be bactericidal in high concentrations. Macrolides tend 
to accumulate within leukocytes, and are, therefore, transported into the site of 
infection. 
PHARMACOKINETICS: 
ABSORPTION &BIOAVAILABILITY : 
 Clarithromycin is acid stable drug and it is rapidly absorbed from the 
gastrointestinal tract after oral administration. 
 The absolute bioavailability of Clarithromycin was approx. 50% because of 
hepatic metabolism. 
 For a single 500 mg dose of clarithromycin, food slightly delays the onset of 
clarithromycin absorption. 
 Absorption of clarithromycin was increased by food. 
 It increases the peak time from approx. 2-2.5 hours. 
 Food also increases the clarithromycin peak plasma concentration by about 24%, 
but does not affect the extent of clarithromycin bioavailability. 
 Food does not affect the onset of formation of anti microbial active metabolite,14-
hydroxy  clarithromycin or peak plasma concentration. 
 Food slightly decrease the extent of metabolite formation, indicated by an 11% 
decrease in area under the plasma concentration time-curve (AUC). 
 Therefore, clarithromycin tablets may be given without regard to food. 
 In non-fasting healthy human subjects (males and females), peak plasma 
concentration, were attained within a 2-3 hours after oral dosing. 
 Steady-state concentration of clarithromycin was attained within 3-4 days. 
 With a 500mg every 8-12 hours dosing, the peak steady state concentration of the 
14-OH clarithromycin is slightly higher (up to 1mcg/ml) and its elimination half 
life is about    7-9 hours.The steady-state concentrations of clarithromycin and 14-
OH clarithromycin observed by administration of 500 mg doses of clarithromycin 
 every 12 hours to adult patients with HIV infection were similar to those 
observed in healthy volunteers. 
 The steady-state concentration of clarithromycin in subjects with impaired hepatic 
function did not differ from those normal subjects. 
 However, 14-OH clarithromycin concentration was lower in hepatically impaired 
subjects. 
 
DISTRIBUTION: 
 Clarithromycin and 14-OH clarithromycin is well distributed to all body tissues, 
middle ear and fluids except CNS. 
 But no data is available for the cerebra spinal fluid (CSF) penetration. 
 It achieves high intracellular concentrations throughout the body. 
 Because of higher intracellular concentrations, tissue concentrations are higher 
than serum concentration. 
 It also diffuses into the prostatic fluid. 
 Protein binding ranges from 40-80% at therapeutic level and it is concentration 
independent. 
 It has unique characteristics of accumulation in macrophages. 
 It mainly concentrates in the liver. 
 Inflammation allows for greater tissue penetration. 
 When clarithromycin 500 mg is given 3 times daily, the clarithromycin plasma 
concentration is increase with respect to the 500 mg twice-daily dosage. 
 Clarithromycin provides tissue concentration that is several times higher than 
circulating drug levels. Increased levels have been found in both tonsillar and 
long tissue. 
 It also penetrates the gastric mucus, levels of clarithromycin in gastric mucus and 
gastric are higher, when clarithromycin is co-administrated with omeprazole than 
when clarithromycin is administrated alone. 
  
METABOLISM: 
 Clarithromycin is metabolized in the liver to several metabolites. 
 The primary metabolic pathways undergoes oxidative N-demethylation and 
hydroxylation at the 14-position to form an active metabolite 14-OH 
clarithromycin, which gives a antibiotic activity. 
 Partially metabolized through hepatic via CYP3A4. 
 Metabolic is saturable, resulting non-linearity pharmacokinetics and longer half-
life are observed after larger doses. 
 Clarithromycin is interference with metabolism of drugs such as theophylline and 
carbamazepine. 
 EXCREATION: 
 Clarithromycin and its metabolites are eliminated by the kidneys as well as the 
liver. 
 The amount of clarithromycin excreted unchanged in the urine ranges from   20- 
40%, and it  depends on the dose and the formulation. 
 Additionally, 14-OH clarithromycin is major excretory metabolite, it accounts for 
10-15% of a dose excreted in the urine as 14-OH clarithromycin. 
 Most of the remainder of the dose is eliminated in faeces, primarily via the bile, 5-
10% of the parent drug is recovered from the faeces. 
 With 500 mg b.i.d, daily dosing urinary excretion is greater (approx 36%). 
 The elimination half life is 3-4 hours for clarithromycin for 250 mg and 5-9 hours 
for 14-OH clarithromycin. 
 The elimination half-life of clarithromycin was about 5-7 hours with 500mg 
administered for every 8-12 hours. 
 It is recommended that the dosage of this drug be adjusted in patients with 
compromised renal function. 
 
  PHARMACODYNAMICS: 
 Clarithromycin is semi synthetic derivative of erythromycin A. It exerts a 
antibacterial activity by binding to the 50s ribosomal sub unit of susceptible 
bacteria and suppresses protein synthesis. 
 
  It is highly potent against a wide variety of aerobic and anaerobic gram-
positive and gram-negative organisms. The minimum inhibitory concentrations 
(MICs) of Clarithromycin are generally two-fold lower than the MICs of 
erythromycin. 
 It is usually bacteriostatic, but may be bacteriocidal depending on the organism 
and the drug concentration. 
 Clarithromycin is usually active against the following organisms in vitro: 
Gram-positive bacteria:  staphylococcus aureus, streptococcus pneumonia. 
Gram-negative bacteria: Haemophilus influenza, Neisseria gonorrhoeae, 
Helicobacter pylori. Other organisms: Mycobacterium avium. 
 
USES 
 It can be used in the treatment of Acute otitis media (AOM), Pharyngitis and 
Tonsillitis, respiratory tract infections, skin infections, Helicobacter pylori 
infections, duodenal ulcer disesase, Bartonella infections, cyprosporidiosis, Lyme 
disease, Mycobacterial infections, Toxoplasmosis, Prevention of bacterial 
endocarditis. 
 It can be used as an alternative to penicillin in patients allergic to penicillin. 
 It can be used in the treatment of Atypical pneumonia, legionnaires pneumonia, 
whooping cough, streptococcal infections, staphylococcus infections, diphtheria, 
syphilis, gonorrhea, campylobacter gastroenteritis, tetanus, anthrax, topical 
infections, etc., 
 
 METHOD OF ADMINISTRATION 
  
Patients with respiratory tract/skin and soft tissue infections. 
Adults: The usual dose is 250 mg twice daily although this may be increased 
to 500mg twice daily in severe infections. The usual duration of treatment is 6 
to 14 days. 
Children older than 12 years: As for adults.Use of clarithromycin 500 mg 
tablets are not recommended for children younger than 12 years. 
Eradication of H. pylori in patients with duodenal ulcers (Adults) 
The usual duration of treatment is 6 to 14 days. 
Triple Therapy: 
i) Clarithromycin (500mg) twice daily and lansoprazole 30mg twice daily 
should be given with amoxycillin 1000mg twice daily. 
ii) Clarithromycin (500mg) twice daily and lansoprazole 30mg twice daily 
should be given with metronidazole 400mg twice daily. 
iii) Clarithromycin (500mg) twice daily and omeprazole 40mg daily should 
be given with amoxycillin 1000mg twice daily or metronidazole 400mg 
twice daily. 
iv) Clarithromycin (500mg) twice daily should be given with amoxycillin 
1000mg twice daily and omeprazole 20mg daily. 
Dual Therapy: 
The usual dose of Clarithromycin is 500 mg three times daily. Clarithromycin 
should be administered with oral omeprazole 40 mg once daily for 14 or 28 
days. 
 Clarithromycin may be given without regard to meals, as food does not 
 
 affect the extent of bioavailability. 
 OVER DOSE: 
 The large amounts of clarithromycin can produce gastro-intestinal 
symptoms. 
 It shows altered mental status, paranoid behaviour, hypokalemia and 
hypoxemia. 
INDICATIONS: 
It is used in the treatment of pharyngitis/tonsillitis acute maxillary sinusitis, 
acute bacterial exacerbation of chronic bronchitis, commonly acquired 
pneumonia, uncomplicated skin infections, disseminated mycobacterial 
infections, Helicobacter pylori and duodenal ulcer disease when used in 
combination with amoxicillin and lansprazole or omeprazole;  Helicobacter 
pylori and duodenal ulcer disease when used in combination with omeprazole 
or ranitidine bismuth citrate, prevention of  mycobacterium avium complex 
(MAC) disease in patients with HIV infections. 
 
CONTRAINDICATIONS: 
 
 Clarithromycin is contra-indicated in patients with known hypersensitivity 
to macrolide antibiotic drugs. 
 Clarithromycin and ergot derivatives should not be co-administered. 
 Concomitant administration of clarithromycin is contraindicated in some 
drugs like: cisapride, pimozide and terfenadine. This may result in QT 
prolongation and cardiac arrhythmias including ventricular tachycardia, 
ventricular fibrillation and Torsade de Pointes. 
 
 
  WARNINGS AND PRECAUTIONS: 
 
 Clarithromycin is  excreted by the liver and kidney. Caution should be 
exercised in administering this antibiotic to patients with impaired 
hepatic or renal function. 
 Prolonged or repeated used of clarithromycin may result in an 
overgrowth of non-susceptible bacteria or fungi. 
 If super-infection occurs, clarithromycin should be discovered. 
 H. pylori organisms may develop resistance to clarithromycin in some 
patients. 
 Deaths have been reported in some such patients. 
ADVERSE EFFECTS: 
Gastrointestinal: abdominal cramps, nausea, diarrhea, anorexia, pancreatitis 
 Genitourinary: vulvovaginal candidiasis, renal failure 
 Cardiovascular System: prolongation of QT interval 
 Hepatic: hepatotoxicity, jaundice 
 Hematologic: eosinophilia, thrombocytosis, lymphopenia 
 Central Nervous System: headache, fatigue 
 Endocrine/Metabolic: hyperglycemia 
 Dermatologic: itching, nail discoloration 
 Others: reversible hearing impairment. 
  
 DRUG INTERACTIONS: 
Clarithromycin inhibit the hepatic metabolism and thereby rise the plasm
carbamazepine, terfenadine, theophylline, digoxin, valproate, and warfarin resulting
in toxicity due to these dugs. 
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CROSCARMELLOSE SODIUM 
Synonyms: 
Ac-Di-Sol; crosslinked carboxymethylcellulose sodium; Explocel; Primellose; 
Vivasol; Solutab. 
Empirical formula: croscarmellose sodium is a crosslinked polymer of 
carboxymethylcellulose sodium. 
Description:  Croscarmellose sodium occurs as an odourless, white or greyish-
white powder. 
Functional category: Tablet and capsule disintegrant. 
Solubility:It is insoluble in water, but rapidly swells to 4-8 times its original 
volume on contact with water and practically insoluble in acetone, ethanol and 
toluene. 
TYPICAL PROPERTIES: 
pH – 5.0 to 7.0 in aqueous dispersions. 
Density – 1.543 g/cm3 
Loss on drying - ≤ 10% 
Content of water-soluble material – 1.0 to 10% 
Settling volume – 10 to 30 ml. 
       Particle size distribution – NMT 2% retained on a #200 mesh 
  NMT 10% retained on a #325 mesh 
PHARMACEUTICAL APPLICATIONS: 
Croscarmellose sodium is used in oral pharmaceutical formulations as a 
disintegrant for capsules, tablets and granules.When used in wet granulations, 
croscarmellose sodium should be added in both the wet and dry stages of the 
process so that the wicking and swelling ability of the disintegrant is best 
utilized.Concentrations of up to 5%w/w of croscarmellose sodium may be used as 
a tablet disintegrant although normally 2% w/w is used  in tablets prepared by 
direct compression and 3%w/w in tablets prepared by a wet granulation process. 
Use Concentration (%) 
Disintegrant in capsules 10-25% 
Disintegrant  in tablets 0.5-5.0% 
 
INCOMPATIBILITIES: 
The efficacy of disintegrants, such as croscarmellose sodium, may be 
slightly reduced in tablet formulations prepared by either the wet granulation or 
direct compression process that contain hygroscopic excipients such as sorbitol. 
 Croscarmellose sodium is not compatible with strong acids or with soluble 
salts of iron and some other metals such as aluminum, mercury and zinc. 
MICROCRYSTALLINE CELLULOSE 
Non proprietary Names       :  Microcrystalline cellulose, cellulosum 
microcrystallinum. 
Synonyms :Avicel PH, celex, cellulose gel, hellulosum microcrystallinum, 
Emcocel,  Fibrocel,  Pharmacel, Vivace, E460. 
 Empirical formula:  (C6H10O5)n  ,   where n =220. 
Molecular weight  : Approx.36000 
Applications  
It is used primarily as a binder/diluent in oral tablet and capsule formulations 
where it is used in both wet granulation and direct compression processes. It also 
has some lubricant, anti-adherent, and disintegrating properties, which make it 
useful in tableting. 
Description 
Microcrystalline cellulose is purified, partially depolymerized cellulose that occurs 
as white, odourless, tasteless, crystalline powder composed of porous particles. It 
is commercially available  in various particle sizes and moisture grades that have 
different properties and applications. 
 
Typical Properties                :          pH – 5.0 to 7.5 
                        Density (true) – 1.512 to 1.668 g/cm3 
                        Angle of  repose – 34.4˚ 
                        Melting point – Chars at 260 to 270˚C 
Moisture content - <5% w/w; hygroscopy. 
Pharmaceutical applications of Microcrystalline cellulose: 
Use Concentration (%) 
Adsorbent 20-90 
Anti adherent 5-20 
Capsule 20-90 
 binder/diluents 
Tablet disintegrant 5-15 
Tablet binder/diluents 20-90 
Table no 4: Properties of some commercially available grades of 
microcrystalline cellulose: 
Grade 
Nominal mean 
particle size (µm) 
Particle size analysis 
Moisture content (%) Mesh 
size 
Amount 
retained(%) 
Avicel PH-101 50 60 
200 
≤1.0 
≤30.0 
≤5.0 
Avicel PH-102 100 60 
200 
≤8.0 
≥45.0 
≤5.0 
Avicel PH-103 50 60 
200 
≤1.0 
≤30.0 
≤3.0 
Avicel PH-105 20 400 ≤1.0 ≤5.0 
Avicel PH-112 100 60 ≤8.0 ≤1.5 
Avicel PH-113 50 60 
200 
≤1.0 
≤30.0 
≤1.5 
Avicel PH-200 180 60 
100 
≥10.0 
≥50.0 
≤5.0 
Avicel PH-301 50 60 
200 
≤1.0 
≤30.0 
≤5.0 
Avicel PH-302 100 60 
200 
≤8.0 
≥45.0 
≤5.0 
 
 
 Incompatibilities:  Incompatible with strong oxidizing agents. 
 
Safety: 
Microcrystalline cellulose is widely used in oral pharmaceutical 
formulations and food products and is generally regarded as a   relatively nontoxic 
and nonirritant material.  
Microcrystalline cellulose is not absorbed systemically following oral 
administration and thus has little toxic potential. Consumption of large quantities 
of cellulose may have a laxative effect, although this is unlikely to be a problem 
when cellulose is used as an excipient in pharmaceutical formulations. Deliberate 
abuse of formulations containing cellulose, either by   inhalation or by injection, 
has resulted in the formation of cellulose granulomas. 
 
HYDROXY PROPYL CELLULOSE 
Non properties 
Names :Hydroxypropyl cellulose,hydroxyl propyl cellulosum 
Synonyms    :   Cellulose, Hydroxypropyl ether, E463,  hydroxypropylcellulosum; 
Hyprolose,  Klucel.  
Molecular weight            :  Ranges from 50000 to 1250000 
Description:Hydroxypropyl cellulose is a white to slightly yellow-coloured, 
odourless and tasteless powder. 
Functional category:Coating agent; emulsifying agent; stabilizing agent; 
suspending agent; tablet  binder; thickening agent; viscosity-increasing agent. 
Solubility: 
   Freely soluble in water below 38˚C, forming a smooth, clear, colloidal solution. 
In hot water, it is insoluble and is precipitated as a highly swollen floc at a 
temperature between 40 and 45˚C. Soluble in many cold or hot polar organic 
solvents such as dimethyl formamide, dimethyl sulfoxide, dioxane, ethanol (95%), 
methanol, propan-2-ol (95%) and propylene glycol. 
Typical properties: 
 pH – 5.0 to 8.5 (1% w/w aqueous solution) 
 Density – 0.5 g/cm3 
 Melting point – Softens at 130˚C, chars at 260-275˚C. 
 Loss on drying - ≤ 5.0%  
 
Pharmaceutical applications: 
Hydroxypropyl cellulose is primarily used in tableting as a binders, film 
coating, and extended release matrix former. It is used as a binder, when it is used 
in 2-6% in both wet and dry granulation processes. The release rate of drug 
increases with decreasing viscosity of Hydroxypropyl cellulose. 5% is used in film 
coated solution. stearic or palmitic acid may be added to ethanolic Hydroxypropyl 
cellulose solutions as plastcizers. A low subistituted Hydroxypropyl cellulose is 
used as a tablet disintegrant. 
Use Concentration (%) 
Extended release matrix former 15-35% 
Tablet binder 2-6% 
Tablet film coating 5% 
Incompatibilities: 
 Hydroxypropyl cellulose in solution demonstrates some incompatibilities with 
substituted phenol derivatives, such as methylparaben and propylparaben. The 
presence of anionic polymers may increase the viscosity of Hydroxypropyl 
cellulose solutions. The compatibility of Hydroxypropyl cellulose with inorganic 
salts varies depending upon the salt and its concentration. It may not tolerate high 
concentrations of other dissolved materials. 
Safety: 
The WHO has specified an acceptable daily intake for Hydroxypropyl Cellulose of 
up to 1500 mg/kg body-weight. Excessive consumption of Hydroxypropyl 
Cellulose may have a laxative effect. 
LD50 (rat, IV): 0.25 g/kg  
LD50 (rat, oral): 10.2 g/kg 
PREGELATINIZED STARCH 
Nonproprietary Names:       Starch, pregelatinized, pregelatinized starch.   
Synonyms :       compressible starch, instastarch, starch 1500,   
pharma-gel, prejel.  
       Chemical name                          :       pregelatinized starch 
       Molecular formula                    :       (C6H10O5)n ,where n=300-1000 
Description : 
Pregelatinised starch occurs as a moderately coarse to fine, white to off-white 
colored powder. It is  odorless and has a  slight characteristic taste. 
Typical properties                 :    pH – 4.5-7.0 
                                                     Density (true) – 1.516 g/ml3 
 Angle of repose- 40o.7″ 
Solubility:  
It is practically insoluble in organic solvents. Slightly soluble in 
coldwater,depending on the degree of pre gelatinization. 
Applications: 
Pregelatinised starch is a modified starch used in oralcapsule and tablet 
formulations as a binder, diluent anddisintegrant. In comparison to starch, grades 
of   Pregelatinisedstarch may be produced with enhance flow and 
compressionCharacteristics such that the Pregelatinised    material may be usedas 
a tablet  binder in dry-compression or direct compression processes. In such 
processes, Pregelatinised starch is self lubricating. However, when it is used with 
other excipients it may be   necessary to add a lubricant to a formulation. Although 
magnesium Stearate 0.25% w/w is commonly used for this  purpose, 
concentrations greater than this may have  adverse effects on tablet strength and 
dissolution.  Therefore, stearic acid is generally the   preferred lubricant with 
pregelatinised starch. 
 
Use Concentration (%) 
Tablet binder (wet granulation) 5–75 
Tablet disintegrant 5–20 
Diluent (hard gelatin capsules) 5–10 
Tablet binder (direct 
compression) 
5–10 
 
POVIDONE 
Nonproprietary Names           :     Povidone (BP, JP, PhEur, USP) 
  Synonyms  : 
Kollidon, Poly [1-(2-oxo-1-pyrrolidinyl) ethylene],polyvidone, 
polyvinylpyrrolidone, 
povidonum, Povipharm, PVP, 1- vinyl-2-pyrrolidinone polymer. 
Molecular Weight:   2500–3000000 
Description : 
Povidone occurs as a fine, white to creamy-white colored, odorless or almost 
odorless,hygroscopic powder.  
Solubility : 
Freely soluble in acids, chloroform, ethanol (95%), ketones,   methanol and water. 
Practically insoluble in ether,  hydrocarbon and mineral oil.  
Functional Category   : 
Disintegrant, dissolution enhancer,  suspending agent and tablet binder. 
Applications : 
In tableting, Povidone solutions are used as binders in wet-granulation processes. 
It is used as a solubilizer in oral and parenteral formulations and has been shown 
to enhance dissolution of poorly soluble drugs from solid-dosage forms. Povidone 
solutions may also be used as coating agents or as binders. Additionally it is used 
as a suspending, stabilizing or viscosity-increasing agent in a number of topical, 
oral suspensions and solutions. The solubility of a number of poorly soluble active 
drugs may be increased by mixing with Povidone. 
Incompatibilities : 
 It forms molecular adducts in solution with sulfathiazole, sodium salicylate, 
salicylic acid, Phenobarbital, tannin and other compounds. 
MAGNESIUM STEARATE 
Synonyms:Magnesium octadecanoate, octadecanoic acid, Magnesium salt and 
stearic acid. 
Description: 
It occursas a fine, white precipitated or milled impalpable powder with a faint 
odour and a characteristic taste. 
Functional categories: Tablet and capsule lubricant. 
Molecular weight: 591.34 
Solubility: 
Practically insoluble in ethanol, ether and water, slightly soluble in warm benzene 
and warm ethanol (95 %). 
Melting point : 117-150°C 
Stability and storage conditions: 
It is stable and should be stored in a well-closed container in a cool, dry place. 
Incompatibilitie: 
Incompatible with strong acids, alkalis and iron salts. 
Applications: 
It is primarily used as a lubricant in tablet and capsules in concentrations between 
0.25 %  and 5 %. It is widely used in cosmetic and food industry. 
ISOPROPYL ALCOHOL 
 Synonyms : 
Dimethyl carbinol, isopropanol, petrohol, 2-propanol and secpropyl alcohol. 
Molecular weight            :  60.1 
Functional category              :   Disinfectant, solvent. 
Description  : 
Isopropyl alcohol is a clear, colorless, mobile, volatile and flammable liquid with  
Characteristic spirituous odor, resembling that of a mixture of ethanol and acetone. 
It has a slightly bitter taste. 
Typical properties  
Antimicrobial activity: 
Isopropyl alcohol is bactericidal; at concentrations greater than 70% v/v it is a 
more effective antibacterial preservative than ethanol (95%). 
Boiling Point                          : 82.4ºC.  
Freezing point                        :  -89.58ºC 
Melting point: -88.58ºC 
Solubility: 
Miscible with benzene, chloroform, ethanol (95%), ether, glycerin and water. 
Soluble in acetone and insoluble in salt solutions. 
Stability and storage : 
Isopropyl alcohol should be stored in an airtight container in a cool, dry place. 
 Incompatibilities: 
Incompatible with oxidizing agents such as hydrogen peroxide and nitric acid, 
which  
cause decomposition. 
TALC 
Nonproprietary Names  : Purified talc, Talc,Talcum 
 
Synonyms: 
Magsil Star, powdered talc, hydrous magnesium calcium silicate, hydrous 
magnesium silicate, purified French chalk, Purtalc, soapstone. 
        Chemical name   : Talc 
        Molecular formula: Mg6 (Si2O5)4(OH)4. 
Description : 
  Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, 
crystalline powder. It adheres  readily to the skin and is soft to the touch and free  
from  grittiness. 
Functional Category:Anticaking agent,  glidant, tablet and capsule diluents, 
tablet and capsule lubricant. 
Typical properties :pH = 7–10 Moisture content: Talc absorbs insignificant of 
water  at 25oC and relativehumidities up to about  90%. 
Solubility: 
Practically insoluble in dilute acids and alkalis, organic solvents, and water. 
 
Applications:  
 Talc was once widely used in oral solid dosage formulations as a lubricant and 
diluents. However, it is widely used as a dissolution retardant in the development 
of controlled-release products. Talc is also used as a lubricant in tablet 
formulations. In a novel powder coating for extended-release pellets and as an 
adsorbent. In topical preparations, is used as a dusting powder. 
 
Use Concentration ( %) 
Dusting powder 5.0–30.0 
Glidant and tablet lubricant 1.0–10.0 
Tablet and capsule diluent 90.0–99.0 
 
 
Incompatibilities :Incompatible with quaternary ammonium compounds. 
 
Stability : 
Talc is a stable material and may be sterilized by heating at160oC for not less than 
1 hour. It may also be sterilized by exposure to ethylene oxide or gamma 
irradiation. Talc should   be stored in a well-closed container in a cool, dry place. 
 
ETHYL VANILLIN 
Nonproprietary Names            :   Ethyl vanillin. 
 Synonyms                                   :  Bourbonal, ethylporta  ethyl protocatechuic  
aldehyde, vanilla. 
       Chemical name                           :      3-ethoxy-4-hydroxy benzaldehyde 
       Molecular formula                     :       C9H10O3 
        Molecular Weight:       166.18 
 Description :white or slightly yellowish crystals with a characteristic intense 
vanilla odor and flavor. 
Typical properties                      :Density(bulk):1.05 
                                                       Melting point: 76-78oC 
                                                               Boiling point : 285oC  
Solubility : 
In chloroform, it is freely soluble. In glycerin, it is soluble. In propylene glycol, it 
is soluble. 
Functional Category                  :     Flavoring agent 
Applications : 
Ethyl vanillin is used as an alternative to vanillin i.e., as a flavoring agent in foods, 
Beverage sand pharmaceuticals. It is also used in perfumery. It possesses a flavor 
and odor approximately three times as intense as vanillin, Hence the quality of 
material necessary to produce an equivalent vanilla flavor may be reduced, 
causing less discoloration to a formulation and potential savings in material costs 
However,exceeding certain concentration limits may impart an unpleasant, slightly 
bitter taste to a product due to the intensity of the ethyl vanillin flavor. 
Incompatibilities : 
Ethyl vanillin is unstable in contact with iron or steel forming a red-colored, 
flavorless compound. 
Stability : 
Stored in a well-closed container, protected from light, in a cool, dry, place. 
PROPYLENE GLYCOL 
 Nonproprietary Names :Propylenglycolum, Propylene glycol 
Synonyms                      : Dihydroxypropane, 2-hydroxypropanol, methylethylene 
glycol,       
methyl glycol, propane-1,2-diol. 
       Chemical name              :   1,2-Propanediol 
          Molecular weight          :     76.09 
Description: 
Propylene glycol is a clear, colorless, viscous, practically odorless liquid with a  
sweet, slightly  acrid taste   resembling that of glycerin. 
        Molecular formula         :   C3H8O2 
Typical properties          :Boiling point: 188oC 
                                                Density: 1.038 g/cm3at 20oC 
                                                Melting point: -59oC 
 
 
 
Solubility : 
Miscible with acetone, chloroform, ethanol (95%) glycerin, and water; soluble at 1 
in 6 parts of  ether, not  miscible with light mineral oil or fixed oils, but   it  will  
dissolve in  some essential oils. 
 
Functional Category : 
Antimicrobial preservative, disinfectant, humectants, Plasticizer, solvent, stabilizer 
for vitamins, water-miscible co solvent. 
 
 Applications : 
Propylene glycol has become widely used as a solvent, extractant, and 
preservative in a variety of parenteral and nonparenteral pharmaceutical 
formulations. It is a better general solvent than glycerin and dissolves a wide 
variety of materials, such as corticosteroids, phenols, sulfa drugs, barbiturates,  
vitamins (A and D), most alkaloids and local anasthetics. As an antiseptic it is 
similar to ethanol and against molds it is similar to glycerin and only slightly less 
effective   than ethanol. Propylene glycol is commonly used as a plasticizer in 
aqueous film-coating formulations.   
Incompatibilities: 
Propylene glycol is incompatible with oxidizing reagent. Such as potassium 
permanganate. 
 
Stability: 
At cool temperatures, propylene glycol is stable in a well-closed container, but at 
high temperatures, in the open, it tends to oxidize, giving rise to products such as  
propionaldehyde, lactic acid, pyruvic acid, and acetic  acid. Propylene glycol is 
chemically stable when mixed  with ethanol (95%), glycerin, or water aqueous 
solutions may be sterilized by autoclaving. 
Storage: 
Propylene glycol is hygroscopic and should be stored in   a well-closed container, 
protected from light, in a cool, dry place. 
 
QUINOLINE YELLOW LAKE 
Synonyms                            : CI food yellow 13, INS No. 104. 
Chemical name                   : Disodium2-(1,3-dioxo-2-indanyl)-6,8-
quinolinesulphates,  
disodium2(2quinolyl)-indane-1,3-dionedisulfonates. 
 Empirical formula              :  C18H9NNa2O8S2 
Molecular weight:  477.38 
Physical state: Yellow powder or granules 
Solubility    : Soluble in water, sparingly soluble in ethanol. 
Melting point       : 150oC 
pH: 8.0-9.0 
Stability and storage: 
Stable under ordinary conditions. The bulk material should  be stored in a well 
closed container in a cool, dry place. 
Applications:  It is used in coloring food, cosmetics and medications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                      4.4. INNNOVATOR PRODUCT SPECIFICATION  
Description: 
 Yellow coloured, ovaloid film-coated tablets. 
 
Composition:Clarithromycin 500 mg. 
 
Excipients used: 
Croscarmellose sodium, cellulose microcrystalline, silicon dioxide, 
povidone, stearic acid, magnesium stearate, talc, hypromellose, 
hydroxypropylcellulose, propylene glycol, sorbitan monooleate, titanium 
dioxide, sorbic acid, vanillin, quinoline yellow E104.  
Physical parameter:The physical dimension is 19.5×9.5mm. 
 
Packaging :It  is available in a 300 µ PVC, PVdC Al foil  blister pack. 
 
Dose and its administration:Patients with respiratory tract infections and skin or 
soft tissue infection.  
Adults (including the elderly): 
 The usual dose is 250 mg twice daily although this may be increased to 
500mg twice daily in severe infections. The usual duration of treatment is 6 
to 14days. 
Children: 
 Children older than 12 years: as same as adults. 
 The use of clarithromycin 500 mg tablets are not recommended for children 
younger than 12 years  
Patients with duodenal ulcer and eradication of H.Pylorii 
  It has both dual and triple therapy. The usual duration of treatment is 6 to 
14 days. 
Shelf life:36 months 
Storage:Store in a cool place, protected from light and moisture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                       4.5.  LIST OF INSTRUMENTS 
Table No. 5: List of instruments 
S. No. Instruments Manufacturers/suppliers 
1 Electronic balance Adventurer Mettler Toleda. 
2 pHMeter Lab India 
3 FTIR spectrophotometer 8300 Shimadzu- corporation, Japan. 
4 
HPLC with PDA/Quartarnary 
system 
Shimadzu - corporation, Japan. 
5 Disintegration tester Electrolab, ED-2L, India 
6 Dissolution apparatus (Disso2000) 
 Lab India dissolution test 
apparatus. 
7 Friability test apparatus Electro lab, ET-2, India. 
8 Bulk density apparatus Thermionic, Campbel Electronics. 
9 Sonicator  Fast clean. 
 
 
 
 
 
 
 
                                         4.6. LIST OF EQUIPMENTS 
Table No. 6: List of equipments 
S. No. Equipments Manufacturer/supplier 
1 Moisture balance OHAVS moisture balance 
2 Vernier caliper Mitutoyo corps, Japan 
3 Hardness tester 
 Monsanto test apparatus. Tab 
machines. 
4 
Stability cum Humidity 
chamber Thermolab India 
5 Fluidized bed dryer Pam Glatt 
 
6 
8 Station tablet compression 
Machine 
Accura,  Ahmedabad 
4.6. EXPERIMENTAL METHODS 
4.6.1. PREFORMULATION STUDIES 67,68 
 Preformulation is usually defined as the science of the physicochemical 
characterization of candidate drugs. Any studies carried out to define the 
conditions under which the candidate drug should be formulated can also be 
termed Preformulation. 
The basic purpose of the Preformulation activity is to provide a rational basis for 
the formulation approaches, to minimize the chances of success in formulating an 
acceptable product and to ultimately provide a basis for optimizing drug product 
quality and performance. The first step in any formulation activity is careful 
consideration of a complete physicochemical profile of the active ingredients 
available, prior to initiating a formulation development activity.   
 
 CONTENTS OF PREFORMULATION STUDIES 
 
 Background – Compound chemical name, chemical structure, 
solvent of recrystallization, purity, therapeutic category. 
 Organoleptic properties – Appearance, color and odor. 
 Microscopic examination – Crystal habit, crystal shape and 
size. 
 Physical properties – Density, particle size, surface area, flow 
properties, hygroscopicity. 
 Solution properties – pH of solution, solubility and 
dissolution rate, drug excipient compatibility study. 
 
A. Evaluation of API 
            The evaluation of clarithromycin was done according to USP. 
Following are some of the important parameters evaluated during preformulation 
studies and results are tabulated in Table No.22 . 
a. DESCRIPTION 
It is the initial evaluation during preformulation studies, which assess the 
color and odor of the substance. This was only a descriptive test.    
b. SOLUBILITY 
 Aqueous solubility is an important physicochemical property of drug 
substance, which determines its systemic absorption and in turns its therapeutic 
drug. 
 
                                     Table No 7: Solubility specifications 
Descriptive terms 
Approximate volume of solvent in 
milliliters per gram  of solute 
Very soluble Less than 1 
Freely soluble From 1 to 10 
 Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1000 
Very slightly soluble From 1000 to 10,000 
Practically insoluble More than 10,000 
 
c. pH 
The pH is the measure of negative logarithm of hydrogen ion concentration 
of an aqueous solution. It is one of the most important factors from the stand point 
of solubility, stability and physiological suitability of a formulation. The pH value 
of a solution is determined potentiometrically by means of a glass electrode. 
d. MELTING POINT 
 The temperature at which the first particle of the substance completely 
melts is regarded as melting point of the substance. The temperature at which the 
first particle start to melt and last particle completely melts is regarded as melting 
range. Melting point of clarithromycin was conducted as per monograph.  
 
e. CHEMICAL NATURE 
 Solubility, stability, bioavailability etc., of a drug substance depends on its 
chemical nature and this information helps to design a suitable dosage form. 
 
f. HYGROSCOPICITY:  It is defined as the ability of a substance to 
absorb moisture from the environmental conditions it is exposed. 
 
Table No8 : Interpretation of results based on % increase in moisture  
S.No. NATURE OF SAMPLE 
 
RESULT OF THE DETERMINATION 
  
g) Particle size determination: 
 Particle size distribution is an important factor which determines number of 
parameters like dissolution rate, bioavailability, content uniformity, flow 
properties, texture and stability of formulation. Number of methods like sieving, 
microscope, laser diffraction methods etc., can analyze the particle size. The 
particle size of the clarithromycin was done by sieving method. 
Table No 9 : Classification of sample was based on the % of sample retained 
or passed on test sieves. 
S.No. NATURE OF SAMPLE RESULT OF DETERMINATION 
1 Coarse powder NLT 95% of the sample mass pass 
through #14 and NMT 40% pass 
through #36  
2 Moderately coarse powder NLT 95% of the sample mass pass 
1 Non hygroscopic No water absorption at RH less than 90%,after 1 
week, water absorption is less than 20% at more 
than 90%RH. 
2 Slightly hygroscopic No water absorption at RH less than 80%,after 1 
week, water absorption is less than 40% at more 
than 80%RH. 
3 Moderately hygroscopic Water absorption doesn’t increase to more than 
5% at RH less than 60% after 1 week, water 
absorption is less than 50% at more than 
80%RH 
4 Very hygroscopic Water absorption occurs at RH as low as 40% 
after 1 week, water absorption is more than 50% 
at more than 80%RH 
 through #25 and NMT 40% pass 
through #60 
3 Moderately fine powder NLT 95% of the sample mass pass 
through #36 and NMT 40% pass 
through #100 
4 Fine powder NLT 95% of the sample mass pass 
through #100 and NMT 40% pass 
through #150 
5 Very fine powder NLT 95% of the sample mass pass 
through #150 and NMT 40% pass 
through #200 
6 Super fine powder NLT 90% by number of particles are 
less than 10µm 
 
h. LOSS ON DRYING 
LOD was performed according to USP monograph. Dry the raw material at 
105º for 2 h. NMT 1.0-1.5 % of its weight must be lost.  
 
 
 
A. Drug-excipient compatibility studies 
           In the tablet dosage form the drug is in intimate contact with one or more 
excipients; the latter could affect the stability of the drug.  Knowledge of drug- 
excipient interactions is therefore very useful to the formulator in selecting 
appropriate excipients. This information may be present for known drugs. For new 
drugs or new excipients, the preformulation scientist must generate the needed 
information. 
 
 
  Physical observation: 
Active ingredient was mixed well with all excipients in binary ratio and small 
portion of this mixed powder was placed in a 2ml of cleaned and dried vial (USP 
Type I). This vial was kept for observation in stability chamber at 30oC ± 2oC / 
65 ± 5% RH,   40oC ± 2oC / 75 ± 5% RH. Mixtures were also placed at 2oC -8oC, 
50oC and room temperature (Control).  Physical observation has been carried out 
visually at the initial stage and after 3 months in 40oC ± 2oC / 75 ± 5% RH and one 
month in 50oC  of exposure to the stated conditions respectively. 
Table No.10: Drug – excipient compatibility studies 
S.No Drug and excipients Ratio 
1 Drug + Microcrystalline cellulose 
PH101 
1:1 
2 Drug + Microcrystalline cellulose 
PH102 
1:1 
3 Drug + Microcrystalline cellulose 
PH112 
1:1 
4 Drug + Hydroxy propyl cellulose 5:1 
5 Drug + Povidone 5:1 
6 Drug + Pregelatinised starch 5:1 
7 Drug + Croscarmellose sodium 10:1 
8 Drug + Talc 10:1 
9 Drug + Aerosil 10:1 
10 Drug + Magnesium Stearate 10:1 
 
 
 
  Chemical compatibility studies by FT-IR : 
Physical compatibility studies were assured by FT-IR studies. The crude drug 
sample, drug-excipient mixtures of the formulation were chosen for the study. The 
FT-IR spectra’s of the above samples were studied after a period of 30 days from 
preparation of the mixtures,to facilitate prompt detection of incompatibility.The 
spectra’s were obtained by preparing Potassium bromide pellets under dry 
condition by using pellet press.    
The spectra of the crude drug sample and that of the drug-excipient mixtures were 
compared to check the incompatibility problems. If there are no changes in peaks 
of mixture when compared to pure drug, it indicates the absence of chemical 
interaction. The FT-IR spectra’s were as shown in Figure No.4 &5. 
4.6.2. SELECTION OF EXCIPIENTS 
Excipients used in the present study were selected according to innovator 
excipient list. Excipients include Croscarmellose Sodium, Povidone, 
Pregelatinised starch, Micro Crystalline Cellulose, Magnesium Stearate, Talc, 
Colloidal silicon dioxide, hydroxyl propyl cellulose in the tablet core. The 
approximate quantity for each excipient to be used was found using finger print 
method. 
FINGER PRINT METHOD  
 Tablet of innovator product has been taken and dissolved in 100 ml of 
water. It was stirred continuously or kept aside for about 60 min.  
 Whatman filter paper No. 42 was selected and it was initially placed in 
desiccator for 10 min, and dried at 105º C for 30 min.  
 Dried filter paper was then weighed and initial weight was noted after 
cooling in desiccator for 10 min.   
  The tablet dissolved in water was filtered and the filter paper was dried 
with the un-dissolved particles.  
 Soon after drying, weight of the paper was noted. The amount of water 
soluble excipients and insoluble excipients can be calculated.  
 
1.6.3. DEVELOPMENT OF PRELIMINARY TRIAL BATCH 
 From finger print method, approximate quantities have been identified and 
trial batch has been taken.  
PREPARATION OF GRANULES FOR COMPRESSION 
 Immediate release tablet of clarithromycin was prepared by wet granulation 
method. All tablet ingredients was accurately weighed as mentioned in Table 
No.11. The average weight of each uncoated tablet was 850 mg. 
 
 
 
 
 
 
 
 
 
 
 
                                      IV.  METHODOLOGY 
4.6.3. Formulation of Clarithromycin  Immediate-release Tablet 
The method used in the formulation of clarithromycin IR tablets was wet 
granulation non-aqueous method. 
 All the batch formulations in these studies are formulated by wet granulation 
method. 
1. Weighing:   
Accurately weigh specified quantity of raw materials clarithromycin, 
croscarmellose sodium in a weighing balance. 
2. Sifting: 
Clarithromycin is sifted through 30#, croscarmellose sodium through 60# 
and placed in a poly bag. Mix the sifted materials for 5min. 
3. Binder preparation: 
      Dissolve Povidone in Isopropyl alcohol under continuous stirring. 
4. Granulation: 
Granulate with required quantity of binder solution by kneading method             
(Hand granulation) or in FBP. 
5. Drying: 
 Dry at an inlet temperature of 60ºC and product temperature of 40ºC in FBP, 
until the moisture content of granules is dried. 
6. Sizing:Using # 20 reduce the size of granules to get the uniform particle 
size. 
7. Mixing & Lubrication: 
 Croscarmellose sodium, pregelatinized starch and microcrystalline cellulose of 
required grade are sifted through # 60 and along with dried granules are mixed 
for 5 minutes.Finally, the above granules are lubricated using specified 
 quantity of magnesium stearate after sifting it through # 60 and mix for 5 
minutes. 
8. Compression:Compress the above granules using 19.5 × 9.5 mm punches 
at an average weight of 850 mg. 
                                      9. PROCESS FLOW CHART 
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                                                                              FORMULATION TRIAL BATCHES 
S.No
. 
Ingredients 
F-1 
(mg/tab) 
F-2 
(mg/tab) 
F-3 
(mg/tab) 
F-4 
(mg/tab) 
F-5 
(mg/tab) 
F-6 
(mg/tab) 
F-7 
(mg/tab) 
F-8 
(mg/tab) 
1 Clarithromycin 500.00 500.00 500.00 500.00 500.00 500.00 500.00 500.00 
2 Croscarmellose sodium 17.00 17.00 17.00 17.00 17.00 17.00 17.00 17.00 
4 Povidone - - 21.00 34.25 35.00 35.00 35.00 35.00 
5 Colloidal silicon dioxide - - - - 6.00 8.50 8.50 - 
6 Hydroxy propyl 
Cellulose 
15.00 20.00 - - - - - - 
7 Microcrystalline cellulose PH101 235.70 229.30 230.00 220.00 - - - - 
8 Croscarmellose sodium 25.50 25.50 - 25.50 25.50 25.50 25.50 25.50 
9 Microcrystalline cellulose PH112 - - 39.45 - - - - - 
10 
Microcrystalline cellulose 
PH102 
50.00 48.00 - 36.00 251.50 249.00 199.00 196.00 
11 Pregelatinised starch - - - - - - 50.00 50.00 
12 Talc - - 8.50 4.25 10.0 8.65 8.65 9.50 
13 Colloidal silicon dioxide 2.55 3.82 4.30 4.50 - - - 9.50 
14 Magnesium stearate 4.25 6.38 4.75 8.5 5.00 6.35 6.35 7.50 
15 Isopropyl Alcohol - - - q.s q.s q.s q.s q.s 
16 Purified water q.s q.s q.s - - - - - 
Average Weight 850 850 850 850 850 850 850 850 
   
 
 
                                                                                Table No.11: Formulation trial batches 
 
   
 
 
                               PERCENTAGE OF INGREDIENTS USED IN TRIAL BATCH FORMULATIONS    
                                            Trial No. 12: Percentage of Ingredients used in trial batch formulations 
S.No
. 
Ingredients MATERIAL  USED  IN  PERCENTAGE  DURING  FORMULATION 
F-1 
(%/tab
) 
F-2 
(%/tab
) 
F-3 
(%/tab
) 
F-4 
(%/tab
) 
F-5 
(%/tab
) 
F-6 
(%/tab
) 
F-7 
(%/tab
) 
F-8 
(%/tab
) 
1. Clarithromycin 58.82 58.82 58.82 58.82 58.82 58.82 58.82 58.82 
2. Croscarmellose sodium 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 
3 Povidone - - 2.47 4.029 4.11 4.11 4.11 4.11 
4. Colloidal silicon 
dioxide 
- - - - 0.70 1.00 1.00 - 
5 Hydroxy propyl 
Cellulose 
2.35 2.35 - - - - - - 
6 Microcrystalline 
cellulose  PH101 
27.14 26.97 27.058 25.88 - - - - 
7 Croscarmellose      
sodium 
3.00 3.00 - 3.00 3.00 3.00 3.00 3.00 
8 Microcrystalline 
cellulose PH112 
- - 4.64 - - - - - 
9 Microcrystalline 
cellulose PH102 
5.88 5.64 - 4.23 29.52 29.29 23.41 23.05 
10 Pregelatinised starch - - - - - - 5.88 5.88 
11 Talc - - 1.00 0.50 1.17 1.01 1.01 1.11 
12 Colloidal silicon 0.3 0.44 0.50 0.529 - - - 1.11 
   
 
 
dioxide 
13 Magnesium Stearate 0.5 0.75 0.55 1.00 0.588 0.74 0.74 0.88 
15 Isopropyl Alcohol - - - q.s q.s q.s q.s q.s 
16 Purified water q.s q.s q.s - - - - - 
  
 
 
4.6.4. COATING SOLUTION FORMULA 
Clarithromycin tablet was coated using the following ingredients mentioned 
in the  Table No.13.  
                     Table No.13: Coating solution formula 
S.No. Ingredients Uses 
Qty/500 Tablet 
(gm) 
1. 
Hydroxy propyl methyl 
cellulose 15 cps 
Film former 
7.20 
2. Ethyl cellulose Coating agent 2.40 
3. Titanium dioxide Opacifizer 2.20 
4. Talc Anti caking agent 1.175 
5. Quinoline yellow (lake) Colour 0.250 
6. Ethyl vanillin Flavour 1.2 
7. Propylene glycol Plasticizer 1.65 
8. Dichloro methane Solvent 144ml 
9. Iso propyl alcohol Solvent 144ml 
 
PROCEDURE  
 Dissolve ethyl cellulose in isopropyl alcohol in a stainless steel vessel and 
disperse HPMC15 cps to the ethyl cellulose solution. 
 Add dichloro methane to ethyl cellulose, HPMC solution and mix well for 
10 minutes under mechanical stirring. 
 Weigh accurately quinoline yellow lake, titanium dioxide and talc. Pass 
through sieve No.60 and triturate in a mortar. Transfer to above stirred 
solution and mix well under stirring. 
  
 
 Add propylene glycol to the above steps and mix well under stirring. 
 Load the tablets in coating pan with baffles fixed and sets the parameters 
according to the suitability of the machine. 
 
4.6.5. FILM COATING PARAMETERS 
Table No.14: Film coating parameters 
Specification Film coated 
Coating pan 12” 
Atomizing air pressure 3 – 4 kg/cm2 
Inlet air temperature 45 – 50ºC 
Outlet air temperature 40 – 45ºC 
Bed temperature 30-35ºC 
Pre-drying in pan 15 min at 45ºC 
Final drying in pan 30 – 45 min at 45ºC 
Post drying in pan 30 min air drying 
Relative humidity 40 ± 5% RH 
 
 
 
4.6.6. OPTIMIZATION OF TRIAL BATCH (F8) BY FULL FACTORIAL 
DESIGN  
 In order to obtain “best” or an “optimized product” nine different 
formulations were generated using a 32 randomized full factorial. Based on 
preformulation study the amounts of croscarmellose sodium (X1) and 
microcrystalline cellulose PH102 (X2) were selected as the independent factors, 
studied at 3 levels each (-1, 0, +1). The percentage drug release (y1) and 
disintegration time (y2) were taken as dependent factors. Experimental trials were 
  
 
performed at all 9 possible combinations of X1 and X2. Batches for factorial design 
are shown in Table No.1579,80 
Table No.15: Formulation trials as per experimental design 
 
 
 
 
 
 
 
 
 
 
 
Trial No. 
 
Coded factor levels 
 
X1 X2 
I -1 -1 
II -1 0 
III -1 1 
IV 0 -1 
V 0 0 
VI 0 1 
VII 1 -1 
VIII 1 0 
XI 1 1 
 
Translation Of Coded Levels In Actual Units 
Coded level -1 0 1 
X1: CCS (%) 2 3 4 
X2:MCC102 (%) 21 23 25 
  
4.6.7. FORMULATION TRIAL BATCHES FOR OPTIMIZED BATCHES 
 
           Table No.16: Formula for optimized batches of F8 
 
 
Ingredients 
Formulation Code  Qty/Tab (mg) 
OF1 OF2 OF3 OF4 OF5 OF6 OF7 OF8 OF9 
Clarithromycin  500 500 500 500 500 500 500 500 500 
Croscarmellose 
sodium 
17.0 17.0 17.0 17.0 17.0 17.0 17.0 17.0 17.0 
Povidone 35.00 35.00 35.00 35.00 35.00 35.00 35.00 35.00 35.00 
Croscarmellose 
sodium  
25.25 25.25 25.25 25.50 25.50 25.50 25.75 25.75 25.75 
Microcrystalline 
cellulose PH102 
194.5 196.5 198.5 194.5 196.5 198.5 194.5 196.5 198.5 
Pregelatinised 
starch 
51.75 49.75 47.75 51.5 49.5 47.50 51.25 49.25 47.25 
Talc 9.50 9.50 9.50 9.50 9.50 9.50 9.50 9.50 9.50 
Colloidal silicon 
 Dioxide 
9.50 9.50 9.50 9.50 9.50 9.50 9.50 9.50 9.50 
Magnesium Stearate 7.50 7.50 7.50 7.50 7.50 7.50 7.50 7.50 7.50 
Isopropyl Alcohol q.s q.s q.s q.s q.s q.s q.s q.s q.s 
TOTAL 850 850 850 850 850 850 850 850 850 
  
Formulation procedure was repeated as per above trial batch and coated. All the 
optimized formulations were evaluated for its description, average weight, friability, 
thickness, hardness, disintegration time, assay and dissolution. 
 
4.6.8. Evaluation of granules of clarithromycin (Precompression parameters) 
It is a very important parameter to be measured because it affects the mass of 
uniformity of the dose. It is usually predicted from flow property, bulk density, 
tapped density, compressibility index and hausners ratio. Clarithromycin granules 
were evaluated by the following method. 
Flow Property Measurements 
It is very important parameter to be measured since it affects the mass of 
uniformity of the dose. It is usually predicted from angle of repose, bulk density, 
tapped density, compressibility index and hausners ratio. 
a. Density (g/ml) 
Granule density, true density and bulk density may influence compressibility, 
tablet porosity, flow property, dissolution and other properties. Higher 
compression load is required in case of dense and hard granules which in turn 
increase the tablet disintegration and drug dissolution time. Density is usually 
determined by Pycnometer. 
b. Bulk density70, 71 
Bulk density is the ratio of the weight of the powder to the bulk volume it 
occupies. It is expressed in g/ml. Weighed quantity of clarithromycin  granules 
was transferred into a 50ml measuring cylinder and the volume occupied by 
granules was measured.  Bulk density was measured using the formula. 
    Pi= M/V0 
  
Where, 
Pi  - Bulk density 
 M - Mass of the blend 
 V0 - Untapped Volume 
c. Tapped density (ρt) 70,71 
 It is done by two methods according to monograph. 
USP TYPE 1 – Fixed drop of 14 ± 2 mm at a nominal rate of 299 drops/min 
USP TYPE 2 – Fixed drop of 3 mm ± 10 % at a nominal rate of 250 drops/min 
Tapped density is achieved by mechanically tapping a measuring cylinder 
containing a powder sample. After observing the initial volume, the cylinder is 
mechanically tapped, and volume readings are taken until little further volume 
change is observed. 
The measuring cylinder containing a weighed quantity of granules (after 
measurement of bulk density) was subjected to 500 taps in tapped density tester     
(Electro Lab USP II). The tapped density was calculated by using the formula,  
 
ρt = m / Vi 
  Where   m = mass of the blend 
Vi = tapped volume 
 
d. Carr’s compressibility index 72,73 
Compressibility is the ability of powder to decrease in volume under pressure. 
Using untapped density and tapped density the percentage compressibility of 
granules were determined, which is given as Carr’s compressibility index. Table 
No: 9 show the percentage compressibility index and its flow characteristics.  
CI=Vi-V0 / Vi × 100 
  
Where,  
CI =  Compressibility index             
V0 = Bulk density                                       Vi= Tapped density   
                                  Table No.17: Compressibility index 
 
 
 
 
 
 
 
 
 
 
e. Hausner’s Ratio 72,73 
It is the measurement of frictional resistance of the drug. The ideal range should 
be       1.2 – 1.5, it was determined by the ratio of tapped density and bulk density. 
 
 
Where,  
Vi - Untapped density  
Compressibility index 
(%) 
Flow characters 
<   10 Excellent 
          11-15 Good 
          16-20 Fair 
          21-25 Passable 
          26-31 Poor 
> 32 Very poor 
  
 V0 - Tapped density 
                                           Hausner’s Ratio 
Table No.18 
Flow character Hausner’s ratio 
 Excellent 1.00 – 1.11 
 Good 1.12 – 1.18 
 Fair 1.19 – 1.25 
 Passable 1.26 – 1.34 
 Poor 1.35 –1.45 
Very Poor 1.46 – 1.59 
Very Very Poor >  1.60 
 
f. Angle of repose 73,74 
Angle of Repose (θ) is the maximum angle between the surface of a pile of 
powder and horizontal plane. It is usually determined by fixed funnel method and 
is the measure of the flow ability of powder/granules. Table No: 19 shows the 
flow properties and corresponding angle of repose. 
Procedure 
Weighed quantity of granules was passed through a funnel kept at a height of 2 cm 
for the base. The powder is passed till it forms heap and touches the tip of the 
funnel. The radius was measured and angle of repose was calculated by using the 
formula. 
                                        θ = tan -1(h/r)                      
  
 Where,     
θ = Angle of repose 
          h = height of the heap of pile,        r = radius of the base of pile    
Table No.19: Flow properties and corresponding angle of repose 
 
 
 
 
 
 
 
 
 
 
g. Moisture content: 
Initially 5g of weighed granules were taken and kept for drying at 105ºC for a 
required time in an oven. Then removed and again reweighed and noted the final 
weight. The difference in weight was noted as moisture content. 
 
Moisture content      =    Initial weight – Final weight     ×   100 
                                                           Initial weight              
Flow 
properties 
Angle of repose (o) 
Excellent 25-30 
Good 31-35 
Fair – aid 36-40 
Passable 41-45 
Poor 46-55 
Very poor 56-65 
Very very poor >66 
  
 4.6.9. Evaluation of tablets 23,24,25,26,27,74,75 
I)   Post compression parameters 
The formulated film coated tablets were evaluated for the following 
physicochemical parameters, 
a. Thickness: 
Thickness mainly depends on die filling, physical properties of material to be 
compressed under compressional force. There is bound to be a small variation in 
the thickness of individual tablet in a batch. But it should not be apparent to the 
unaided eye. The thickness and diameter were measured by using vernier 
calipers.75 
b. Hardness: 
Tablet requires certain amount of strength or hardness, measured by Monsanto 
hardness tester. Ten tablets were randomly picked from each formulation and 
evaluated for hardness during manufacturing and are expressed in kg/cm2.75 
c. Friability: 
Friability was performed by using friability test apparatus, normally pre-weighed 
ten tablets were placed in the plastic chamber of friabilator. This was then 
operated for 100 revolutions. Tablets were dropping from a distance of six inches 
with each revolution. Tablets are then dusted and reweighed. Loss of less than 1% 
in weight is considered to be acceptable. 76 
Initial wt. – Final wt. 
Initial wt. 
d. Weight variation test: 
F (%) = × 100 
  
Twenty tablets were selected randomly and weighed individually. Calculate 
average weight and compare the individual tablet weight to the average. Not more 
than two of the individual weights deviate from the average weight by more than 
the percentage shown in Table No.: 20 and none deviates by more than twice the 
percentage. 
 
 
 
Table No.20: Percentage deviation for weight variation test 
Average weight of Tablets (mg) Max. Percentage deviation (%) 
       130 or less            ± 10 
More than 130 - Less than 324            ± 7.5 
      324 or more             ±5 
 
II)  In-vitro dissolution studies: 77,78 
 Dissolution for clarithromycin: 
Dissolution system: 
 Apparatus     : Dissolution Apparatus USP Type – II (Paddle) 
 Speed           : 50 RPM 
Medium         : 900 ml of Acetate buffer pH 5.0 
Temperature : 37°C ± 0.5°C 
 Time             :  30 Minutes 
 
  
Procedure : 
Preparation of Buffer solution: 
13.61 gm of Sodium acetate trihydrate was dissolved in 1L of purified water in 1L 
volumetric flask and mix. Then Adjust with 0.1M acetic acid to apHof 5.0 
Preparation of  Standard solution: 
62.50 mg of clarithromycin USP working Standard  was  accurately  weighed  and 
transferred in a 100ml volumetric flask and dissolved using methanol, and made 
up to the volume using dissolution medium.  
From the above solution, 10 ml was taken in a 50 ml volumetric flask and made up 
to a volume with mobile phase.  
Preparation of sample solution: 
Apparatus was set as per above conditions, one tablet placed in each of the six 
dissolution vessels and started the dissolution test. After completion of  30 
minutes, 20 ml of the solution was withdrawn from dissolution bowl. The filtrate 
was collected after discarding first few ml of the filtrate. From this 5 ml of the 
filtrate was diluted to 25 ml with mobile phase. 
Chromatographic system: 
Apparatus     :  HPLC 
Column      :  A stainless steel column (250×4.6mm) packed with Octa decyl silane 
(C18) bonded to porous silica. 
Flow rate       : 1.0 ml/min 
Column  oven temperature : 50oC 
Injection volume : 50µL 
  
Wave length  :  210 nm 
 
Preparation of buffer solution: 
9.113 gm of monobasic potassium phosphate was accurately  weighed and 
dissolved in 1000 ml of water and its pHwas adjusted to 4.0 with dilute ortho 
phosphoric acid. 
Preparation of mobile phase: 
 Take 650 ml from the above buffer solution and 350 ml of methanol was mixed 
well, and filtered and degassed. 
 
Procedure: 
50 microlitres of filtered portion of the standard solution and sample solution were 
separately injected into the HPLC system. The chromatogram was recorded and 
the responses were measured for the major peaks. The amount of drug  release of 
clarithromycin USP was calculated in percentage with respect to label claim by 
using the following expression. 
Calculation forclarithromycin: 
AT            WS           10         900         25           P                       
=                   X             X            X         X               X                   
      AS              100         50          1              5             100                            
=    ———————— mg of clarithromycin released. 
% of drug released =   mg of drug released X 100 
                                             LA 
  
Where, 
          AT   = Area of the clarithromycin in sample solution 
        AS   = Average area of the clarithromycin peak for standard solution  
        WS = Weight  taken in mg for standard solution 
         P     = Percent purity of clarithromycin on as such basis 
         LA = Labeled amount. 
System suitability: 
1. % RSD of five replicate injections peak should not be more than 2.0% 
2. The theoretical plate for clarithromycin peaks should not be less than 750. 
3. The tailing factor for clarithromycin peaks should not be more than 2.0 
 
III)  ASSAY (BY HPLC)  
Preparation of buffer solution: 
9.113 gm of monobasic potassium phosphate was accurately weighed and 
dissolved in 1000 ml of water and its pH was adjusted to 4.0 with dilute ortho 
phosphoric acid.  
Preparation of mobile phase: 
  650 ml of the above buffer solution and 350 ml of methanol was mixed well, 
filtered and degassed. 
Preparation of standard  stock solution: 
  
62.50 mg of clarithromycin USP working Standard  was  accurately  weighed  and 
transferred in a 100ml volumetric flask and dissolved using methanol, and made 
up to the volume using mobile phase.  
Preparation of standard solution: 
10 ml of standard stock solution was taken in a 50ml volumetric flask and made 
up to a volume with mobile phase.  This solution contains about 125µg of 
clarithromycin per ml. 
Preparation of resolution  solution: 
62.5 mg of clarithromycin USP related compound A was weighed in a 50ml 
volumetric flask and dissolved using methanol. Then 10 ml of this solution and 10 
ml of standard stock solution was transferred to a 50 ml volumetric flask and made 
up to the volume with mobile phase.  
Preparation of sample solution: 
20 tablets were weighed and crushed to a fine powder, then weighed 438.0 mg of 
tablet powder (i.e., equivalent to about 250 mg of clarithromycin) was transferred 
to 200 ml volumetric flask, then  about 75 ml of methanol was added and 
sonicated for 30 minutes. Diluted with methanol to volume and mixed well, and 
allowed the solution to settle  insoluble matter. Then transferred 5ml of 
supernatant solution to a 50 ml volumetric flask and made up to volume with 
mobile phase and mixed well. Passed the solution  through filter paper and used 
this solution as assay preparation. 
Chromatographicconditions 
Column    :  A stainless steel column (250×4.6mm) packed with Octa decyl silane 
(C18) bonded to porous silica. 
  
Flow rate   : 1.0 ml/min 
Column oven temperature : 50oC 
Injection volume : 50µL 
Wave length :  210 nm 
Procedure: 
50 microlitres of filtered portion of the resolution solution, standard solution and 
sample solution were separately injected into the HPLC system. The 
chromatogram was recorded and the responses were measured for the major peaks. 
The content of per tablet was calculated using the following expression. 
Calculation: 
 
         AT              WS            10        200         5             P                
=                    X           X            X            X           X           X Avg.wt X100 
AS              100           50        WT         50         100 
 
=    ———— mg of clarithromycin per tablet. 
Where, 
AS  =   Average area of the clarithromycin peak in standard solution,  
sAT  =   Area of the clarithromycin peak in sample solution,  
WS  =  Weight of clarithromycin taken for standard in g,  
WT =  Weight of clarithromycin taken for sample in g, 
P     =  Percent purity of clarithromycin on as such basis. 
 
System suitability: 
  
1. % RSD of five replicate injections peak should not be more than 2.0% 
2. The theoretical plate for clarithromycin peaks should not be less than 750. 
3. The tailing factor for clarithromycin peaks should  NLT 0.9 and NMT 1.5. 
4. The resolution between clarithromycin and clarithromycin related 
compound A should not be less than 2. 
 
4.6.10.  SIMILARITY FACTOR 81,82,83  
 In recent years, FDA has placed more emphasis on a dissolution profile 
comparison in the area of post-approval changes and biowaivers. Under 
appropriate test conditions, a dissolution profile can characterize the product more 
precisely than a single point dissolution test. A dissolution profile comparison 
between pre-change and post-change products for SUPAC related changes, or with 
different strengths, helps assure similarity in product performance and signals 
bioinequivalence. 
Among several methods investigated for dissolution profile comparison, f2 
is the simplest. Moore and Flanner proposed a model independent mathematical 
approach to compare the dissolution profile using two factors, f1 and f2. 
The difference factor (f1) calculates the percentage difference between the 
two curves at each time point and is a measurement of the relative error between 
the two curves: 
 
                                       f1= {[Σt=1n | Rt – Tt |] / [Σt=1n Rt]} .100 
 
where, n is the number of time points, Rt is the dissolution  value of the reference 
batch at time t and Tt is the dissolution value of the test batch at time t. 
  
The FDA and EMEA defined similarity factor as a "logarithmic reciprocal 
square root transformation of one plus the mean squared (the average sum of 
squares) differences of drug percent dissolved between the test and the reference 
products" 
In other words, the similarity factor (f2) is a logarithmic transformation of 
the sum-squared error of differences between the test Tt and reference products 
Rtover all time points. It represents closeness of two comparative formulations. 
Generally similarity factor in the range of 50-100 is acceptable according to US 
FDA. 
f2 = 50. log {[1 + (1/n) Σt=1n (Rt-Tt) 2 ] -0.5 .100} 
 
 
General procedure: 
i. Determine the dissolution profile (5 units each) of the test and reference 
products. 
ii. Using the mean dissolution values from both the curves at each time 
interval, calculate the difference factor (f1) and similarity factor (f2) 
using the above equations. 
iii. For curves to be considered similar, f1 values should be close to 0, and 
f2 values should be close to 100. Generally, f1 values up to 15 (0-15) and 
f2 values greater than 50 (50-100) ensures sameness or equivalence of 
the two curves. 
     The comparative dissolution study was performed to determine the 
similarity of dissolution profiles for the immediate release clarithromycin 
(OF7) between the innovator product.The results are tabulated in Table No. 
34. 
  
If there is more than 85% drug release at 15 mins after dissolution, the FDA 
guidelines provides that the comparative dissolution study can be surpassed. 
Hence the study is not performed for the immediate release layer as there is 
>85% drug release at 15 min. 
4.6.11. STABILITY STUDIES28 
        Stability of a drug has been defined as the ability of a particular formulation, 
in a specific container, to remain within its physical, chemical, therapeutics and 
toxicological specifications. The purpose of stability testing is to provide evidence 
on how the quality of a drug substance or drug product varies with time under the 
influence of a variety of environmental factors such as temperature, humidity and 
light, and to establish a retest for the drug substance or a shelf life for the drug 
product and recommended storage conditions. The ICH guideline recommends the 
following storage conditions for stability studies: 
Table No.21: Stability conditions according to ICH guidelines 
S. No. Study Storage Condition 
1. Long term 25°C±2°C / 60%RH±5%RH 
2. Intermediate 30°C±2°C / 65%RH±5%RH 
3. Accelerated 40°C±2°C / 75%RH±5%RH 
 
As per ICH guidelines, the samples for stability analysis must be exposed 
to an environment of 40˚C±2˚C / 75%RH±5% RH for a period of 6 months. As 
per the standard protocol the samples must be analyzed at 0, 1, 2, 3 and 6 months 
time points.  
        Accelerated stability studies were performed for the final tablets. As per ICH 
guidelines, tablets were packed in Alu-Alu blister and required blisters were 
  
placed into the stability chamber. The samples were analyzed at 0, 1, 2 and 3 
months time points. 
 
Test Performed 
 Physical parameters (Description, Hardness, Thickness, Friability, DT). 
 Physiochemical parameter (In-vitro Dissolution Study) 
 Chemical parameter (Assay) 
The results of the stability studies are tabulated in Table Nos. 35, 36 and 38. The 
data was analyzed for any significant change in the values from the initial data.  
                    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
V. RESULTS AND DISCUSSIONS 
5.1. PREFORMULATION STUDIES 
                         a. Evaluation of API 
Table No.22: Raw material analysis 
S. 
No 
Test Observation 
1. Description White  to off-white crystalline powder 
2. Chemical nature 
 
Chemical structure  
 
Molecular formula C38H69NO13 
Molecular weight 748.95 
IUPAC name 6-O-Methyl erythromycin A 
3. Loss on drying NMT 1.0-1.5% 
4. Solubility 
Practically insoluble in water, Soluble in acetone, Slightly 
soluble in methanol, ethanol and acetonitrile. 
5. Particle size of  Distribution Moderately coarse powder 
6. Hygroscopicity Non-hygroscopic. 
7. Melting point 217-220
oC 
 
  
8. pH (1%) 8-9 
 
b. Drug-Excipient compatibility studies (Physical observation) 
Table No. 23: Compatibility studies of Clarithromycin with excipients. 
  
The preformulation studies of the excipients were mixed with the drug and kept in 
different conditions, the observed results are as follows: 
 
S.No 
 
Drug+Excipien
t 
 
Paramete
r 
Initial Value 
of Parameter 
Condition 
 
Comments 
1st Month 3rd Month 
50°
C 
2-
8°C RT 40°C 
1 Clarithromycin 
Color 
change 
No color 
change No color change Compatible 
2 
Microcrystallin
e Cellulose 
PH101 
Colorchan
ge 
No color 
change No color change Compatible 
3 
Cross 
caramellose 
Sodium 
Color 
change 
No  color 
Change 
No color change Compatible 
4 Povidone 
Color 
change 
No color 
Change 
No color change Compatible 
5 Hydroxy Propyl 
Cellulose 
Color 
change 
No color  
Change 
No color change Compatible 
6 MCC  PH112 
Color 
change 
No color 
Change 
No color change Compatible 
7 Pregelatinised 
starch 
Color 
change 
No color 
Change 
No color change Compatible 
8 Talc 
Color 
change 
No color 
Change 
No color change Compatible 
9 Aerosil 
Color 
change 
No color 
Change 
No color change Compatible 
10 Magnesium 
Stearate 
Color 
change 
No color 
Change 
No color change Compatible 
  
i) FT-IR studies: The FT-IR spectra of the crude drug samples and the drug-excipient mixtures are as shown below. 
                  Figure No. 4: FT-IR spectra of clarithromycin USP- Raw material. 
 
  
  
Figure No. 5:  FT-IR spectra of clarithromycin and its excipients. 
 
  
Table No. 24:      FTIR spectrum of clarithromycin USP- raw material 
 
Wave Number (cm-1) Functional Group 
3470 cm-1 OH stretching 
2976 cm-1 CH aliphatic 
1729 cm-1 C=O stretching 
1458 cm-1 CH3 bending 
1266 cm-1 CH2 bending 
1096 cm-1 C—N stretching 
1052 cm-1 C—O stretching 
 
Table No. 25:   FTIR spectrum of clarithromycin + excipients 
Wave Number (cm-1) Functional Group 
3465 cm-1 OH stretching 
2975 cm-1 CH aliphatic 
1730 cm-1 C=O stretching 
1459 cm-1 CH3 bending 
1228 cm-1 CH2 bending 
1026 cm-1 C—N stretching 
1011 cm-1 C—O stretching 
 
 
 
  
Inference:   Pure Clarithromycin spectra showed sharp characteristic peaks at                        
3470, 2976, 1729, 1458, 1266, 1096, 1011 cm-1. These peaks are also prominent in 
the FTIR spectra’s of the physical mixtures containing clarithromycin and other 
excipients in the final formula. This indicates that there is no interaction between 
the drug and excipients from both physical observation and FT-IR studies. 
 
5.2.  FINGER PRINT METHOD 
 
Weight of tablet taken, a                 = 922mg 
Weight of empty filter paper, b                = 1.1966 mg 
Weight of empty filter paper after drying, c   = 1.1903 mg 
Weight of insoluble portion after dried, d   = 780 mg 
Weight of soluble portion, e               =   (a-d)   = 142 mg 
Weight of insoluble portion  apart from drug (wt. of core tablet – label claim) = 
780-500 
                                                                                                                              
=280 mg. 
 
INFERENCE 
 From the above results and nature of the excipient solubility, trial formula 
has been developed and formulated.  
 
 
  
 
5.3. EVALUATION OF PRECOMPRESSION PARAMETERS 
A. Evaluation of clarithromycin granules:  The prepared clarithromycin granules were evaluated for the following 
parameters, which includes Bulk density, Tapped density, Compressibity Index, Hausner’s ratio and Angle of repose. 
a) For clarithromycin trial batches 
Table No.26: Pre compression parameters for clarithromycin trial batch 
S.No Formulation Code 
Bulk density 
(gm/cc) 
Tapped 
density 
(gm/cc) 
Carr’s     
index (%) 
Hausner’s 
ratio 
Angle of       
repose            
(o) 
Moisture 
content         
(%) 
1 F1 0.472±0.001
5 
 
0.556±0.012 
 
15.10±0.95 
 
1.17±0.18 
 
33.30±0.60 1.26±0.02 
2 F2 0.484±0.000
5 
0.574±0.047 
 
15.67±0.61 
 
1.18±0.017 
 
34.93±0.68 
 
1.05±0.05 
3 F3 0.510±0.001
5 
 
0.575±0.010 
 
11.30±0.11 
 
1.12±0.037 
 
33.73±0.27 
 
0.93±0.03 
4 F4 0.532±0.001
5 
 
0.611±0.013 
 
12.92±0.41 
 
1.14±0.02 
 
33.40±0.73 0.85±0.01 
5 F5 0.486±0.001 
 
0.563±0.013 
 
13.67±0.02 
 
1.15±0.02 
 
31.43±0.51 
 
0.83±0.02 
6 F6 0.534±0.012 
 
0.593±0.012 
 
9.94±0.01 
 
1.11±0.02 
 
31.7±0.34 0.78±0.03 
7 F7 0.522±0.025 
 
0.589±0.02 
 
11.37±0.05 1.12±0.03 30.14±0.29 
 
0.86±0.01 
  
8 F8 0.532±0.013 0.595±0.013 10.58±0.02 1.11±0.01 30.91±0.01
3 
0.84±0.01 
                                                                                                               *All the values are expressed as mean±SD, n=3. 
Inference: The values of compressibility index, Hausner’s ratio and angle of repose of all the batches indicate a good flow 
property of the granules. 
   B. For optimized batches (Uncoated tablets) 
Table No.27: Precompression parameters for optimized batch 
S.No. 
Formulatio
n 
Code 
Bulk 
Density 
*(g/cc) 
Tapped 
Density 
*(g/cc) 
Compressibilit
y 
Index (%)* 
Hausner’s 
Ratio* 
Angle of 
Repose* 
(º) 
Moisture 
content         
(%) 
1. OF1 
0.483±0.001
5 
 
0.568±0.01
1 
 
14.96±0.01 1.17±0.01 30.10±0.60 0.85±0.01 
2. OF2 
0.487±0.000
5 
0.554±0.00
7 
 
12.09±0.05 1.13±0.04 32.43±0.68 0.88±0.03 
3. OF3 
0.510±0.001
5 
 
0.585±0.01
5 
 
12.82±0.10 1.14±0.02 32.33±0.27 0.82±0.05 
4. OF4 
0.532±0.001
5 
 
0.610±0.03
5 
 
14.66±0.02 1.14±0.01 31.40±0.73 0.77±0.01 
5. OF5 0.532±0.001 
 
0.595±0.01
3 
10.58±0.02 1.11±0.01 30.44±0.51 0.83±0.05 
  
 
                                                                                             * All the values are expressed asmean ± SD (n=3). 
Inference: The values of compressibility index, Hausner’s ratio and angle of repose of all the batches indicate an 
good flow property of granules. 
 
6. OF6 0.534±0.012 
 
0.603±0.01
1 
 
11.44±0.03 1.12±0.10 30.33±.34 0.88±0.05 
7. OF7 0.577±0.025 
 
0.647±0.06
2 
 
12.17±0.02 1.12±0.08 34.54±0.29 0.87±0.05 
8. OF8 0.575±0.013 
 
0.662±0.02
3 
13.14±0.01 1.15±0.06 33.61±0.15 0.79±0.02 
9. OF9 0.576±0.014 
 
0.656±0.01
6 12.19±0.01 1.13±0.03 32.51±0.11 
0.86±0.01 
  
5.3.  EVALUATION FOR POST COMPRESSION PARAMETERS  
a) Post compression parameters for clarithromycin trial (F1-F8) batch for uncoated tablets. 
         Table No. 28:     Post compression parameters for clarithromycin trial batch uncoated tablets         
Formulation 
code 
Average 
Weight(mg) 
Thickness 
(mm)* 
Hardness 
(kg/cm2)* 
Disintegrati
on(min) 
Friability 
(%) 
Weight 
variation 
(mg) 
Assay 
(%) 
F1 851 6.00 ±0.02 
 
9.3±0.67 
 
1.50±0.02 - 850.0±0.06 
 
- 
F2 849 5.98±0.03 
 
9.5±0.35 
 
1.43±0.01 - 849.9±0.74 
 
- 
F3 853 5.96±0.08 
 
10.0±0.61 
 
1.54±0.02 - 849.73±0.7
1 
 
- 
F4 854 5.98±0.12 
 
10.0±0.5 
 
1.40±0.01 
 
0.2±0.01 850.16±1.1
9 
 
101.12 
F5 851 6.01±0.05 
 
9.5±0.5 
 
1.22±0.02 
 
0.1±0.01 850.93±1.0
6 
 
100.34 
F6 848 6.04±0.187 
 
9.5±0.35 
 
1.26±0.029 
 
0.32±0.02 849.59±1.1
8 
 
99.01 
F7 849 6.06±0.202 
 
9.5±0.612 
 
1.26±0.049 
 
0.27±0.01 850.3±1.47 
 
103.23 
F8 852 6.01±0.11 
 
9.5±0.35 1.28±0.02 
 
0.15±0.02 851.03±0.9
9 
 
104.67 
  
b) Evaluation of clarithromycin coated tablets of trial batch 
     Table No. 29:  post compression parameters for coated tablets 
 
 
 
 
 
 
 
                                                                                                            * All the values are expressed asmean ± SD (n=6). 
Inference: The values of both uncoated and coated parameters in above all batches are in limits. 
 
 
S.No. 
Formulation 
code 
Average 
Weight 
(mg) 
Thickness 
(mm)* 
Disintegration 
(min) 
Weight 
variation 
(mg) 
Assay 
(%) 
1 F4 874 6.16±0.031 
 
2.24±0.019 
 
874.18±1.59 
 
98.87 
2 F5 877 6.11±0.053 
 
2.25±0.029 
 
876.93±1.46 
 
98.79 
3 F6 877 6.17±0.064 
 
2.25±0.02 
 
876.09±1.35 
 
103.28 
4 F7 876 6.13±0.039 
 
2.27±0.057 
 
875.93±1.67 
 
102.76 
5 F8 874 6.14±0.037 
 
2.25±0.046 
 
877.03±0.99 
 
104.54 
  
c)  For optimized batches (coated tablets) 
Table No. 30: Post compression parameters for optimized batches. 
All the values are expressed as* Mean ± SD (n=6);   # Mean ± SD (n=3). 
S.No. Formulation Code 
Average 
Weight * 
(mg) 
Thickness 
(mm)* Weight variation test* (mg) 
Disintegration test* 
(min) 
Assay# 
(%) 
1. OF1 875.54 6.12±0.026 
 
876.10±0.94 
 
3.12±0.04 100.04±0.07 
2. OF2 876.27 6.17±0.031 
 
876.56±1.44 
 
3.06±0.06 99.99±0.01 
3. OF3 875.08 6.13±0.025 
 
876.03±1.23 
 
3.27±0.05 102.99±0.01 
4. OF4 874.79 6.19±0.065 
 
874.75±1.35 
 
2.53±0.023 101.99±0.01 
5. OF5 877.02 6.16±0.031 
 
875.03±0.08 
 
2.25±0.018 104.54±0.02 
6. OF6 877.32 6.11±0.053 
 
874.0±1.12 
 
2.24±0.01 103.30±0.63 
7. OF7 876.15 6.17±0.064 
 
876.06±1.05 
 
2.16±0.02 101.69±0.01 
8. OF8 874.14 6.13±0.039 
 
875.89±1.08 
 
2.08±0.04 103.01±0.04 
9. OF9 876.21 6.14±0.037 
 
876.55±0.64 
 
1.55±0.05 103.68±0.01 
  
Inference: The values of optimized coated tablet parameters in above all batches are in limits. 
  
 
5.4.   INNOVATOR PRODUCT SPECIFICATIONS 
Table No.31: Evaluation specifications for  Innovator product 
 
 
TEST PARAMETERS RESULTS 
Description Oval shaped, yellow coloured tablet 
Hardness 9-10 (kg/cm2) 
Thickness 6.0-6.3 mm 
Assay of Clarithromycin  by HPLC  
(% label claim) 
99.34 % ( NLT 75% to NMT 105%) 
Percentage drug release of 
Clarithromycin IR tablets 
Time (in 
min) 
Percentage drug 
release 
5 80.88 
10 95.46 
15 97.55 
20 99.34 
30 102.56 
  
5.6. COMPARATIVE DISSOLUTION PROFILE STUDIES 
a)  Comparative dissolution profile study of clarithromycin coated tablets 
with innovator product 
 Table No. 32: Comparative dissolution profile study of clarithromycin coated 
tablets with innovator product 
All the values are expressed as * Mean SD (n=6). 
Figure No. 6: Comparative dissolution profile study of clarithromycin coated 
tablet (F8) with innovator product 
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S.No. 
Formulation 
Code 
Cumulative percentage  Drug release (min)* 
5th 
min 
10th 
Min 
15th 
min 
20th 
min 
30th 
min 
1. F4 68.55±0.12 81.57±0.72 91.23±0.85 92.67±0.23 96.34±0.12 
2. F5 68.84±0.45 84.32±0.75 91.75±0.12 93.62±0.83 98.38±0.34 
3. F6 71.04±0.64 80.56±0.53 91.89±0.64 95.33±0.87 99.47±0.46 
4. F7 69.38±0.87 82.74±0.65 93.40±0.25 96.65±0.37 102.11±0.47 
5. F8 69.19±0.16 85.31±0.25 96.27±0.76 98.36±0.65 101.15±0.72 
6. Innovator 80.88±0.04 95.46±0.14 97.55±0.41 99.34±0.23 102.56±0.34 
  
b) Comparative dissolution profile study of clarithromycin optimized coated tablets  with innovator product  
TableNo. 33: Comparative dissolution profile study of clarithromycin optimized coated tablets with innovator product. 
 
 
 
 
 
 
 
 
 
 
 
 
All the values are expressed as* Mean SD (n=6). 
S.No. 
Formulation 
Code 
Cumulative percentage  Drug release(min)* 
5th 
min 
10th 
min 
15th 
min 
20th 
min 
30th 
min 
1. OF1 70.28±0.62 83.61±0.65 95.91±0.96 97.56±0.21 99.38±0.23 
2. OF2 69.04±0.613 83.19±0.64 94.67±0.64 96.73±0.36 98.21±0.56 
3. OF3 68.65±0.649 82.59±0.63 94.76±0.54 96.91±0.15 98.57±0.18 
4. OF4 70.59±0.651 84.68±0.54 95.03±0.48 98.21±0.65 100.46±0.35 
5. OF5 69.19±0.16 83.31±0.25 95.27±0.76 97.36±0.65 101.15±0.27 
6. OF6 68.59±0.621 82.11±0.46 94.98±0.56 96.02±0.64 99.83±0.74 
7. OF7 70.83±0.354 84.96±0.57 95.45±0.54 98.46±0.66 101.62±0.48 
8. OF8 69.54±0.633 83.63±0.56 94.86±0.64 96.08±0.67 100.28±0.13 
9. OF9 68.73±0.458 82.77±0.68 93.88±0.26 96.46±0.64 101.14±0.25 
10. Innovator 80.88±0.04 95.46±0.14 97.55±0.41 99.34±0.23 102.56±0.34 
  
 Figure No.7: Comparative dissolution profile study of clarithromycin optimized 
coated tablet (OF7) with innovator product 
 
 
  
Inference: Dissolution profile of optimized coated tablets found to be similar with  
all above batches and innovator drug dissolution profile. Among the entire 
optimized batches, formulation OF7 has been selected for calculating similarity 
factor, since it shows faster disintegration time and rapid drug release. Similarity 
factor was calculated by comparing the in-vitro drug release profile for batch OF7 
with the innovator product.
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5.7. COMPARITIVE DISSOLUTION PROFILE  
This comparative dissolution study performed between the formulation OF7 and the innovator product. The 
formulation OF7 has been selected for comparative dissolution study, since it shows faster disintegration time and rapid drug 
release compared to all optimized tablets. 
Table No. 34: Comparative dissolution profile for OF7 and innovator product.  
 
 
 
 
 
 
 
                                                                        * Mean ± SD (n=6)                  
Inference: The comparative dissolution profile of similarity and dissimilarity profile was studied for formula OF7 and 
innovator product. The satisfactory resultwas observed.  
 
S.No. Dissolution time 
points 
Formulation 
OF7* 
Innovator 
product* 
OF7 
Dissimilarity 
factors (f1) 
0-15 
Similarity 
factor (f2) 
50-100 
1. 5th min 70.83 80.88 
5.147 59.658 
2. 10th min 84.96 95.46 
3. 15th min 95.45 97.55 
4. 20th min 98.46 99.34 
5. 30th min 101.62 102.56 
  
 
5.8. STABILITY STUDIES 
      Accelerated stability studies were carried out for the OF7 batch. As per ICH 
guidelines, the stability study data are listed below. 
a) Stability study  data for  batch –OF7 (Post compression parameters) 
Table No. 35:Stability studies for post compression parameters of OF7 
Post  compression 
Parameters 
Storage condition 
40˚C ± 2˚C / 75% RH ± 5% RH 
Initial 1st month 2nd month 3rd month 
Description * * * * 
Average weight (mg) 875.0±0.85 875.0±0.96 876.0±0.05 876.15±0.02 
Hardness(Kg/cm2) 10.0±0.09 9.5±0.77 9.5±0.44 9.5±0.09 
Thickness(mm) 6.17±0.037 
 
6.17±0.12 6.16±0.34 6.16±0.02 
Disintegration time (sec) 2.16±0.046 
 
2.20±0.06 2.14±0.08 2.06±0.05 
                                                                             * yellow coloured film-coated tablet. 
 
Inference:The accelerated stability study results were found to be satisfactory and within 
limits.  
 
 
 
 
 
  
 
 
b) In vitro dissolution study –OF7, stability batch 
Table No. 36: Stability studies of invitro dissolution profile for OF7  
 
Figure No. 8: In vitro dissolution study –OF7, stability batch 
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Dissolution 
Time points 
(min) 
Storage condition 
40˚C ± 2˚C / 75% RH ± 5% RH 
Initial 1st month 2nd month 3rd month Innovator 
5 70.83±0.354 69.45±0.21 65.27±0.70 61.66±0.28 77.34±0.18 
10 84.96±0.57 84.23±0.54 83.65±0.69 81.57±0.42 93.67±0.22 
15 95.45±0.54 94.89±0.16 93.45±0.21 92.03±0.27 95.27±0.76 
20 98.46±0.66 98.24±0.02 97.82±0.25 97.56±0.92 98.87±0.01 
30 101.62±0.48 101.03±0.06 100.67±0.62 99.73±0.12 100.56±0.05 
  
 
Inference: There are no significant changes in the physical parameters and analyzed 
characteristics of the tablets are observed during the period of study. The drug  invitro 
dissolution profile  also  remained  within  the  limits,  at the end  of 3rd month  of  40˚C ± 
2˚C / 75% RH ± 5% RH . From this stability studies, it is concluded that the formulated 
tablets are stable. 
c) Assay – OF7, stability batch 
Table No. 37: Stability studies for assay of OF7.  
 
 
 
 
 
Figure No. 9: Assay – OF7, stability batch 
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Storage condition 
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Initial 1st month 2nd month 3rd month 
OF7 101.69 100.27 99.74 96.88 
Innovator 99.34 98.70 97.62 96.47 
  
 
 
Figure No.10: Assay – Innovator, stability batch 
 
 
Inference: 
The drug assay  profile  were came  within the limits, at the end of 3rd month of 40˚C ± 
2˚C / 75% RH ± 5% RH . From this stability studies, it is concluded that the formulated 
tablets are stable. 
 
5.9. CHROMATOGRAM OF CLARITHROMYCIN TABLETS 
1. Chromatogram of clarithromycin and their related substance 
Table No. 38: Chromatogram of clarithromycin and their related substance 
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Months 
Assay(Innovator) 
Assay(Innovator)
S.No. Name Retention 
time(min) 
Area(AU) Area(%) Tailing 
factor 
1 Clarithromycin 
standard 
8.845 338781 40.81 1.99 
2 Clarithromycin 
related compound 
A 
12.812 491391 59.19 2.13 
  
 
 
 
 
 
Figure No. 11: Chromatogram of clarithromycin and their related substance  
 
 
 
 
2.  Clarithromycin   (OF7) stability batch chromatograms (dissolution profile) 
Table No. 39: Clarithromycin stability batch chromatograms (dissolution profile) 
S.No. Name of the 
sample 
Retention 
time (min) 
Area (AU) Area (%) Tailing 
factor 
  
1 Standard 8.955 338875 100.00 1.306 
2 OF7 initial 8.953 306763 100.00 1.39 
3 OF7 1st month 8.956 304985 100.00 1.38 
4 OF72nd month 8.951 304521 100.00 1.34 
5 OF7 3rd month 8.950 301055 100.00 1.30 
 
 
a) Chromatogram of clarithromycin standard (Standard) 
Figure No. 12: Chromatogram of clarithromycin standard (Standard) 
 
 
 
 
 
 
  
 
 
 
 
 
 
b) Chromatogram of clarithromycin tablets (40oC ±2%,75%±5% RH)-3rd 
month 
Figure No. 13: Chromatogram of clarithromycin tablets 
 
 
3. Clarithromycin (OF7) stability batch chromatograms (Assay) 
Table No. 40:  Clarithromycin stability batch chromatograms (Assay) 
 
S.No. Name of the sample Retention Area(AU) Area (%) Tailing 
  
time (min) factor 
1 Standard 8.956 338875 100.00 1.38 
2 OF7   initial 8.957 346898 100.00 1.35 
3 OF7 1st month 8.958 341938 100.00 1.35 
4 OF72nd month 8.952 337231 100.00 1.34 
5 OF7 3rd month 8.954 328283 100.00 1.38 
 
 
 
 
a) Assay of clarithromycin (standard)-(40oC ±2%, 75%±5% RH)-3rd month 
Figure No. 14: Chromatogram of assay for clarithromycin  (Standard) 
 
 
 
b) Assay of clarithromycin tablet (40oC ±2%, 75%±5% RH)-3rd month 
 
  
Figure No. 15: Chromatogram of assay of clarithromycin tablets 
 
 
 
                                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
SUMMARY 
 
The present study of  clarithromycin film coated tablets were developed with a 
view to deliver the drug immediately. The film coated immediate release tablets were 
evaluated and the details of results and discussion were given in the following sections.  
 
Drug Excipient-Compatibility Study: 
The FT-IR spectrum of clarithromycin raw material was shown in Fig.No. 4. The 
spectrum of Clarithromycin raw material  shows the presence of peaks at 3470 cm-1, 
2976 cm-1 1729 cm-1 , 1458 cm-1 ,1266 cm-1, 1096 cm-1  and 1052 cm-1 of OH, CH, 
C=O, CH3, CH2, C-N, C—O stretching respectively.  
The FT-IR spectrum of the combined clarithromycin and excipients was shown in 
the Fig.No 5. The spectrum shows the presence of peaks at 3465 cm-1 , 2975 cm-1, 1730 
cm-1 , 1459 cm-1 ,1228 cm-1 ,1026 cm-1 and 1011 cm-1of OH, CH, C=O, CH3, CH2,    
C-N, C—O stretching respectively, indicating there is no interation between the drug and 
the excipients. 
Observation of clarithromycin tablet formulation during inprocess: 
Initial batches, that is F1 to F3 were formulated with wet granulation by aqueous 
method with hydroxy propyl cellulose (2.35%) as a binder, MCC PH 101 is used as a 
diluent. These formulations  shown a sticking problem during inprocess compression, 
which may be due to high moisture content and  low amount of  lubricants. 
 Therefore, the next trial (F4) were again formulated with non-aqueous granulation with 
povidone (4.029%) and lubricants like aerosil (0.529%), magnesium stearate (1.0%), talc 
(0.5%). In this trial, sticking was not observed. But roughness is observed during 
compression.  
In the trial F5, in this formulation, MCC PH 101 is replaced by MCC PH 102 (4.23%) 
and colloidal silicon dioxide (0.7%) in the granulation. In addition, lubricants are 
  
increased to avoid the sticking problem during compression. Here, all the parameters 
were found satisfactory.  
In the F6 trial, some amounts of lubricants are increased in both upper and lower 
granulation parts. All the parameters were found to be satisfactory and this batch tablets 
were kept for stability studies. During stability studies, dissolution was failed in the 1st  
month for 40oC ± 2oC/75% ± 5%. Because, while dissolution, the tablet breaks into 2-3 
parts and not disintegrated uniformly. The percentage drug release was also less 
compared to initial month of stability studies. This problem may be due to insufficient 
disintegrates in the formulation. 
In the trial F7, this procedure is also same as trial F5. However, in this 
formulation, the concentration of MCC PH102 is decreased and pre-gelatinized starch 
was included in the lubrication part of the formulation for better disintegration during the 
dissolution. In this, all the parameters were found satisfactory during pre-compression 
and post-compression. During dissolution of 1st month of stability studies, all the tablets 
were not disintegrated evenly and divided in to 2 to 3 parts. This may be due to presence 
of aerosil in the upper granulation part.  
In the trial F8, in this formulation, colloidal silicon dioxide was replaced from 
granulation part to the lubrication part. In addition, increase the lubricants concentration 
to avoid sticking. In this trial, all the parameters were found satisfactory at initial stages. 
Therefore, to know the best formula, formulation F8 undergoes the 32 randomized full 
factorial optimization studies. Based on preformulation studies, the amounts of 
croscarmellose sodium (X1) and  microcrystalline cellulose PH102 (X2) were selected as 
the independent factors, studied at 3 levels each (-1, 0, +1). The percentage drug release 
(y1) and disintegration time (y2) were taken as dependent factors.  
Optimized batches were coded as OF1, OF2 OF3, OF4, OF5, OF6, OF7, OF8 and 
OF9. The Precompression and post compression studies was performed for all the 
optimized batches. Results were found to be similar for all the optimized batches and 
innovator product.  From these studies, OF7 was selected and compared all the evaluation 
profiles with the innovator product during the period of  stability studies.    
  
EVALUATION OF BLEND MATERIALS OF CLARITHROMYCIN TABLETS: 
 
The angle of repose of formulation blends of clarithromycin F1 to F8 were in the 
range of 30.14±0.29° to 34.93±0.68°. The bulk density, tapped density, Carr’s index, 
hausners ratio were found in the range of 0.472 to 0.534g/cc, 0.55 to 0.61g/cc,           10 – 
15.33g/cc and 1.11-1.18 respectively. It reveals that all the formulation blends were 
having good flow characteristics and flow rates. 
The results of granule evaluation were given in Table No. 26. 
Tablet characteristics of clarithromycin uncoated IR tablets: 
The tablets of different formulation were subjected to various evaluation tests such 
as thickness, hardness, friability and drug content. All the formulations of clarithromycin 
showed uniform thickness.  
The hardness and percentage friability of all batches (F4 to F8) of clarithromycin 
ranged from   9.5 – 10.0 kg / cm2 and 0.1 – 0.3 % respectively.  The disintegration of all 
batches (F4 to F8) of clarithromycin is found in limits 1.22-1.54. 
The drug content of clarithromycin uncoated tablets was found to be uniform 
among all the formulations which ranges from 99.01% –104.67%. The evaluation results 
of clarithromycin uncoated IR tablet were given in Table No. 28 
Tablet characteristics of clarithromycin coated IR tablet: 
The tablets of different formulation were subjected to various evaluation tests such 
as thickness, disintegration and drug content. All the formulations of clarithromycin 
showed uniform thickness.  
The disintegration time of all batches (F4 to F8) of clarithromycin is found within limits         
2.24-2.27. 
The drug content of clarithromycin coated tablets was found to be uniform among 
all the formulations, which ranges from 98.87% – 104.54%. The evaluation results of 
clarithromycin IR tablet were given in Table No. 29. 
 
  
Tablet characteristics of clarithromycin optimized coated IR tablet: 
The tablets of different formulation were subjected to various evaluation tests such 
as thickness, disintegration and drug content.  
The disintegration of all batches (OF1 to OF9) of clarithromycin are found within limits 
2.08-3.06 min 
The drug content of clarithromycin coated tablets was found to be uniform among 
all the formulations which ranges from 99.99% – 104.54%. The evaluation results of 
clarithromycin IR tablet were given in Table No. 30.  
In-vitro drug release study from F4 to F8 
The in vitro drug release of all the formulations of clarithromycin from F4 to F8 at        
5th, 10th, 15th, 20th and 30th minutes was found to be in the range of 68.55-69.19%, 
81.57-85.31%, 91.23-96.27%, 92.67-98.36%, and 96.34-101.15% respectively. Among 
all the formulations, F8 were found to be the best (F8-Clarithromycin-500mg, CCS-17 
mg, povidone - 35mg, CCS (L) - 25.50mg, MCC102-196mg, pregelatinized starch (L)-
50mg, talc - 9.50 mg, aerosil l-9.50 %, magnesium stereate-7.50mg) since its release was 
satisfactory i.e., 69.19%,85.31%, 96.27%,98.36%, 101.15%  at 5th,10th,15th,20th,30th 
minute. 
Comparison of clarithromycin IR tablets (OF7) with innovator product 
Table No: 33 gives the comparison of in-vitro dissolution profile of clarithromycin 
IR batch (OF7) with the innovator product. The drug release of clarithromycin IR  tablet 
was found to be 70.83%, 84.96%, 95.45%, 98.46%, and 101.62% at 5th, 10th, 15th, 20th, 
30th min respectively. 
The drug release of innovator product was found to be 80.88%, 
95.46%,97.55%,99.34% and 102.56% at 5th,10th,15th,20th ,30th minute respectively for 
clarithromycin . 
In Table No:33, the formulation OF7 shows the dissimilarity factor f1 and similarity 
factor f2 values are within the specified limits (i.e., 5.147 and 59.658) when compared 
with the innovator product. Hence, formulation OF7  was selected for stability studies.  
  
Stability Studies 
The clarithromycin  immediate  release  tablets (OF7)  was  kept  on  stability  at                       
40° C/ 75 % RH and the three month accelerated condition results were found to be 
satisfactory. The stability study data’s were depicted in the Table No.35-37. 
 
 
 
                                                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CONCLUSION 
 
The objective of the present study was to formulate, optimize and evaluate 
clarithromycin immediate release film coated tablet. 
Literatures regarding, clarithromycin tablet dosage form preparation, excipients 
selection, manufacturing method, etc., has been collected and reviewed. 
In this work, selection of excipient was done based on standard innovator product 
cited from pack insert. Excipients include croscarmellose sodium, povidone, 
pregelatinized starch, microcrystalline cellulose, colloidal silicon dioxide, magnesium 
stearate. Quantities of the excipients were selected by performing finger print method, 
which is an IHS of Fourrts India Laboratory. 
Preformulation studies have also been performed to study the nature of API and 
compatibility of API with excipients by physical observation and FT-IR studies. The 
results show that API was compatible with all the excipients selected. 
The tablets were formulated by wet granulation method using the selected 
excipient quantities. The formulated tablets were tested for both pre-compression 
parameters and post compression parameters as per requirements of standards. 
Pre-compression parameters such as bulk density, tapped density, compressibility 
index, Hausner’s ratio and angle of repose were performed and found to show excellent 
flow properties. 
Post compression parameters such as weight variation, hardness, thickness, 
friability, disintegration, drug content and percentage drug release were performed and 
found to be within the limits. 
The formulated trial batch was taken for optimization by full factorial design. i.e., 
croscarmellose sodium (X1) and microcrystalline cellulose sodium (X2) as 2 independent 
variables at 3 levels -1, 0 and +1. 
  
Optimized batches were coded as OF1, OF2, OF3, OF4, OF5, OF6, OF7, OF8 and 
OF9. The in vitro dissolution study was performed for all the optimized formulations. 
Similarity is found in the results of all the optimized formulations and innovator product. 
Among the entire optimized batches, formulation OF7 has been selected for calculating 
similarity factor, since it shows better results (i.e., faster disintegration time and rapid 
drug release) than other optimized batches. Similarity factor was calculated by comparing 
the in-vitro drug release profile for batch OF7 with the innovator product. The 
dissimilarity factor f1 value of 5.147 and similarity factor f2 value of 59.658 indicates 
that the two products were similar in in-vitro drug release. 
The tablets of  OF7 optimized batch was subjected to accelerated stability studies 
as per ICH guidelines. The results of stability studies showed that there were no 
significant changes in the physical and chemical parameters studied. 
From this study, it was concluded that optimized clarithromycin tablet (OF7) 
containing croscarmellose sodium (3.029%) and pregelatinized starch (6.029%) could be 
manufactured with reproducible characteristics from batch to batch. 
 
 
 
 
 
 
 
 
 
 
 
  
FUTURE STUDY 
  
The finding of the present study has initiated the company to go in for scale up 
trial. Based on the reproducible results produced from batch to batch the company will 
decide to launch the product in the future. 
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